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ABSTRACT
In fibroblasts, transforming growth factor β-1 (TGFβ1) signals via canonical and noncanonical pathways to promote wound healing or hyper-contractile responses resulting in
scars. The oral cavity however does not scar and fibrotic responses such as gingival
hyperplasia are characterized by a hyper-proliferative response. The involvement of noncanonical, TGFβ-activated kinase-1 (TAK1) - mediated TGFβ1 signaling in gingival
fibroblasts has not been previously examined. Here I show that TAK1 selective inhibitor
(5Z)-7-Oxozeaenol blocks TGFβ1-induced expression of wound healing and fibrotic marker
CCN2 (connective tissue growth factor) in gingival fibroblasts. Genome-wide expression
profiling revealed that essentially all TGFβ1 induced genes were in fact sensitive to TAK1
inhibition in gingival fibroblasts (139/147) including those involved in proliferative and
wound healing responses. This data was confirmed using RT-qPCR to detect mRNA
expression as well as functional cell proliferation assay. (5Z)-7-Oxozeaenol might be
investigated in the treatment of gingival hyperplasia in the future.

KEYWORDS: TGFβ1; TAK1; (5Z)-7-Oxozeanol; fibrosis; wound healing; CCN2; gingival
fibroblasts; proliferation
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1. Introduction
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1.1 Overview of physiological wound healing
Disruption or damage of the anatomical structure and function of a tissue or organ
is characterized as a wound (Lazarus et al., 1994; Robson et al., 2001). Wound healing is
an orderly physiological process in all tissues and organs of the body in response to
injury, with the goal of anatomical and functional restoration of that tissue or organ (Guo
and DiPietro, 2010; Velnar et al., 2009). Aside from the liver, eye and skeletal tissues,
this process of repair is generally conserved across various tissues and organs and has
been described as having four phases: hemostasis/coagulation, inflammation,
proliferation and resolution/remodeling (Guo and DiPietro, 2010; Hunt et al., 2000;
Robson et al., 2001; Velnar et al., 2009; Wynn 2008). It has been hypothesized that
failure to terminate the repair program leads to excessive deposition of connective tissue
in place of the normal parenchyma resulting in the development of fibrotic scars (Guo
and DiPietro, 2010; Leask 2008; Wynn 2008). Interestingly, in contrast to every other
adult tissue, the oral cavity does not scar in response to injury (Egusa et al., 2010; Guo et
al., 2011a, 2011b; Schor et al., 1996; Wikesjo et al., 1992). Understanding the differences
in wound healing responses among different tissue types is of importance for future
clinical benefit (Ebisawa et al., 2011; Eslami et al., 2009; Guo et al., 2011a, 2011b; Schor
et al., 1996). At present however, relatively little is known about the fundamental
mechanisms underlying scarless repair in the gingiva, thus the discussion of wound
healing and fibrotic mechanisms in the gingiva are best considered in the context of
dermal repair. What is currently known about cutaneous and gingival tissue repair,
fibrosis and structural anatomy are thus compared and discussed below.

.

3

1.2 Comparative anatomy: structure of skin and gingiva
1.2.1 Structural anatomy of skin
Skin, the largest organ of the body is comprised of three layers: the epidermis,
dermis and hypodermis (Wolff et al., 2007) (Figure. 1.1). The epidermis, composed of
keratinized stratified squamous epithelium is of ectodermal origin (Wolff et al., 2007).
Depending on the thickness of the skin, the epidermis consists of five (thick skin: palms,
soles) or four (thin skin) outermost to innermost layers: stratum corneum, stratum
lucidum (in thick skin only), stratum granulosum, stratum spinosum and stratum basale
(Vi 2010; Wolff et al., 2007). Analogous to the skin, the superficial layer of the gingiva is
comprised primarily of keratinocytes with occasional melanocytes, Langerhans’ cells
(antigen presenting cells) and neurosensory cells. It is further classified into four sublayers similarly to skin: stratum corneum, stratum granulosum, stratum spinosum and
stratum basale (Nanci, 2013; Squier and Kremer, 2001). Differentiation of keratinocytes
as they move from the deep (stratum basale) to superficial (stratum granulosum) layers
constitutes the squamous appearance of the layer, resulting in keratin squames which are
shed in the stratum corneum (Nanci, 2013; Squier and Kremer, 2001; Thomson, 2012).
Dermis, mesodermal in origin, is a strong and flexible connective tissue layer
below the epidermis and above the hypodermis which is composed of loose connective
and fatty tissues (Gosain et al., 2004; Harper and Grove, 1979; Montagna and Parakkal,
1974; Wolff et al., 2007). Fibroblasts, macrophages, mast cells, extracellular matrix
(ECM) (types I and III collagen, elastin and fibronectin, proteoglycans), glycoproteins,
nerve fibers and blood vessels are found within the dermis (Gosain et al., 2004;
Palaiologou et al., 2001). The dermis is further subdivided into papillary and reticular
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Figure 1.1. Comparative anatomy: Structure of (A) skin and (B) gingival
masticatory mucosa in cross section. Epithelium layer is the outermost layer of the
gingival masticatory mucosa while the outermost layer in the skin is known as the
epidermis. The dermis (skin) or lamina propria (gingiva) are the connective tissue layers
below the outermost layer. (A) Reprinted from: Kendall AC, Nicolaou A. 2013. Bioactive
lipid mediators in skin inflammation and immunity. Progress in Lipid Research. Volume
52,

Issue

1,

pages

141–164

http://dx.doi.org/10.1016/j.plipres.2012.10.003

with

permission

from

Elsevier.
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sub-layers in the superficial to deep order. The former forms ridges at the point of contact
with the epidermis and contains thin, poorly organized collagen fibers and higher
collagen type III to type I ratio as well as many more fibroblasts, which show higher
proliferation and enzymatic activity (Gosain et al., 2004; Harper and Grove, 1979;
Montagna and Parakkal, 1974; Vi 2010; Weber et al., 1984). The reticular region, located
above the hypodermis, is characterized by a decreased collagen type III to type I ratio,
thick and organized collagen fibers and fibroblasts that show reduced proliferation
capacity yet increased contractile responses (Harper and Grove, 1979; Vi 2010; Weber et
al., 1984). Hair follicles as well as sweat and sebaceous glands are also found within the
dermis.
1.2.2 Structural anatomy of gingiva
Gingival tissue is classified as the oral mucosa surrounding the tooth which acts
as a protective barrier (mechanical damage and environmental factors) for the underlying
tissues (Nanci, 2013; Seoane Leston et al., 2002; Squier and Kremer, 2001). Gingival
mucosa which faces the oral cavity is further known as masticatory mucosa. The
epithelial and connective tissue layers of gingiva are organized in a similar fashion to that
of the skin. Masticatory mucosa is comprised of the superficial keratinized stratified
squamous epithelium layer which is supported by the underlying lamina propria layer,
analogous to the dermis layer of the skin (Nanci, 2013; Squier and Kremer, 2001;
Thomson, 2012). The basal lamina further forms the interface between the two layers
(Nanci, 2013; Squier and Kremer, 2001; Thomson, 2012) (Figure 1.1). Located below
the lamina propria, the submucosal region in the gingiva is analogous to the hypodermis
layer of the skin (Nanci, 2013; Squier and Kremer, 2001; Thomson, 2012). The lamina
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propria is organized in a similar fashion to the dermis. Conversely, unlike skin, gingival
masticatory mucosa lacks hair follicles as well as sweat and sebaceous glands (Seoane
Leston et al., 2002).

1.3 Pathological wound healing: overview of fibrosis
Wound healing can be affected by multiple factors, generally characterized as
local (pertaining to the wound itself) or systemic (pertaining to the overall health of the
organism) (Guo and DiPietro, 2010). Simultaneous processes of inflammation, tissue
remodeling and regeneration serve as indicators of fibrotic disease, loosely defined by a
time-dependent increase of total collagen deposition which exceeds the rate of collagen
degradation (Wynn, 2008). The excessive production, remodeling and contraction of the
ECM further leads to excessive scarring, the hallmark feature of fibrotic diseases (Krieg
et al., 2007; Leask 2008). The resulting fibrotic scars exhibit a reduction in original
elasticity of the tissue, are fairly acellular and replace normal tissue architecture while
diminishing its function (Singer and Clark, 1999; Toriseva et al., 2007). It is estimated
that close to 45% of deaths in developed countries are attributed to some form of the
disease condition which affects the function of multiple organs (Pinzani 2008; Wynn
2008). Fibrotic diseases are also the largest group of diseases to which there is no
established therapy (Leask 2008; Pinzani 2008; Wynn 2008). Diabetic nephropathy,
pulmonary fibrosis, liver cirrhosis, atherosclerosis, systemic sclerosis/scleroderma,
gingival hyperplasia and even hypertension are some of the numerous examples of
fibrotic diseases affecting individual organs as well as the entire organism (Leask 2008,
2011; Pinzani 2008).
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Although fibrosis is a complex disease involving many mediators, it is thought
that myofibroblasts, fibroblast-like contractile cells, as well as three main extracellular
factors TGFβ1, endothelin-1 and CCN2 (connective tissue growth factor) represent a
common mechanism underlying the onset and progression of fibrosis (Krieg, et al.,
2007).
1.3.1 Fibrotic lesions contain abundant myofibroblasts
The cell type responsible for persistent fibrosis is the myofibroblast, a contractile
and secretory cell which is characterized by the increased intracellular staining for αSmooth Muscle Actin (α-SMA), incorporated into stress fibers that span the length of the
cell (Gabbiani 2003). α-SMA is a contractile protein which attaches to the ECM through
fibronexus/focal adhesion structures (the in vivo and in vitro junction respectively) on the
cell surface and promotes the excessive adhesion and mechanical force generation at the
site of wounding, thus promoting wound closure and scar formation (Hinz, 2006, 2007,
2010; Hinz and Gabbiani, 2003; Hinz et al., 2007; Krieg et al., 2007; Shi-wen et al.,
2012). Focal adhesions, composed of actin filaments, act as a link between the contractile
α-SMA protein inside the cell and the ECM outside (Hinz and Gabbiani, 2003; Liu et al.,
2009; Parsons, 2003, Tomasek, et al., 2002). They contain two other important
components: integrins (the cell surface receptors for ECM) and focal adhesion kinase
which promotes adhesive signaling responses and subsequent fibrosis (Chen et al., 2005;
Hinz and Gabbiani, 2003; Liu et al., 2009; Mimura et al., 2005; Parsons 2003; Tomasek,
et al., 2002). Essentially, the myofibroblast phenotype in vitro and in vivo is characterized
by the appearance of a contractile cytoskeleton accompanied by the de novo expression
of α-SMA positive stress fibers, integrin attachments to the ECM, replacement of N-
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cadherin adhesions with the formation of bigger OB-cadherin (cadherin-11)-type cell-cell
adhesions as well as the formation of large, so–called “supermature” focal adhesions
(Figure 1.2) (Hinz 2007, 2010; Hinz et al., 2004).
Increased myofibroblast numbers in the dermis correlate with the excessive
production of collagen and other ECM components, contraction of ECM and granulation
tissue formation (Hinz and Gabbiani, 2003; Hinz et al., 2007; Krieg et al., 2007;
Tomasek, et al., 2002). Increased myofibroblast numbers in the skin of systemic sclerosis
patients also directly correlates with the extent of local collagen deposition and the
Rodnan skin score — which measures the extent of scarring and disease progression
(Hinz et al., 2012; Kissin, et al., 2006; Krieg et al., 2007).
In physiological wound healing, myofibroblasts begin their regression and
undergo apoptosis with the onset of wound re-epithelialization. In contrast, during
fibrosis myofibroblasts persist, resulting in the excessive production and remodeling of
the ECM (Desmoulière et al., 1995; Hinz et al., 2012; Krieg et al., 2007).
1.3.2 Origin of myofibroblasts
Several theories have been proposed relating to the origin of myofibroblasts,
possibly the earliest point of control in fibrotic disease progression and most accurate
indication of the onset of fibrosis (Figure 1.2) (Hinz et al., 2007; 2012; Krieg et al.,
2007). For example, the dermal myofibroblasts that are detected in response to wound
healing and/or scleroderma have been purported to arise as a result of: 1) differentiation
of resident dermal fibroblasts via signaling in response to growth factors such as TGFβ1;
2) recruitment of circulating fibrocytes, bone marrow (BM)-derived circulating cells or
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Figure 1.2. Myofibroblast characterization and possible origins. Although several
theories have been proposed relating to possible myofibroblast progenitors, fibroblast to
myofibroblast differentiation (driven by TGFβ1) is considered to be a predominant
source of myofibroblasts in wound healing and fibrosis. Expression of adherens
junctions, super-mature focal adhesions and α-SMA incorporation into stress fibers are
indicative of myofibroblast phenotype. (Adapted with permission from Figure 2. One
cell, multiple origins. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML,
Gabbiani G. 2007. The myofibroblast: one function, multiple origins. Am J Pathol. 2007
Jun;170(6):1807-16. DOI: 10.2353/ajpath.2007.070112; http://www.elsevier.com)
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resting mesenchymal precursor cells to the specific tissue site and subsequent
differentiation into myofibroblasts via induction by cell-ECM contacts or cytokines; 3)
activation of vascular pericytes and smooth muscle cells concomitant with the repair of
damaged vasculature in response to injury or 4) clonal selection of resting myofibroblasts
(Abe et al., 2001; Direkze et al., 2003; Hinz et al., 2001, 2007; Krieg et al., 2007;
Rajkumar et al., 2005).
Of interest still is the traditional view of fibroblast to myofibroblast
differentiation, likely to be the predominant process in physiological wound healing and
repair. This connective tissue repair process is primarily driven by fibroblasts which are
resident connective tissue cells. These cells differentiate into a contractile myofibroblast
phenotype in response to mechanical tension and growth factors such as TGFβ1 (Hinz
2007, 2010; Krieg et al., 2007; Leask 2008).

1.4 Fibroblast cells
Fibroblasts are connective tissue cells of mesodermal origin, loosely defined as
cells of “spindle shape” capable of forming an extracellular matrix rich in type I and/or
type III collagen, adhering to ECM and lacking markers for other cell lineages (Alberts et
al., 1994; Chang, et al., 2002; Ebisawa et al., 2011). They are the most versatile
connective tissue cell type which can be classified as Loose (in adipose tissue), Fibrous
(in tendons, ligaments and cartilage) and Specialized (in bone and blood) that together
create a structural framework of body architecture (Alberts et al., 1994). Certain so-called
“immature” fibroblasts (sometimes referred to as mesenchymal cells) from various body
regions are capable of differentiating into other connective tissue cell types, often co-
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existing in a mixed population with the mature fibroblasts (Alberts et al., 1994; Egusa et
al., 2010).
Fibroblasts are considered essential for the wound healing process (Abe et al.,
2001). Deficiency in fibroblast proliferation and wound closure leads to ulceration.
Conversely, abnormal proliferation and/or differentiation into myofibroblasts lead to the
excessive production of collagen and other ECM proteins as well as contraction of ECM
resulting in fibrosis (Krieg et al., 2007; Leask, 2008).
1.4.1 Fibroblast to myofibroblast differentiation
Growth factors such as TGFβ1, biomechanical tension and matrix signaling are
three known factors required for fibroblast to myofibroblast differentiation (Gabbiani
2003; Lagares et al., 2012; Tomasek et al., 2002). Importantly, the disruption of the
architecture and composition of ECM, which normally acts as a stress shield for the
resident fibroblasts, leads to fibroblast activation and migration into the wound site (Hinz
2007; Hinz et al., 2007; Tomasek et al., 2002; Werner and Grose, 2003).

1.5 The role of TGFβ1 in wound healing and fibrosis
TGFβ1 was first identified in 1983 and has been characterized as a member of
TGFβ superfamily which also includes Nodals, Inhibins, Activins, Bone Morphogenetic
Protein (BMP), Growth and Differentiation Factor (GDF), Mullerian inhibitory substance
(MIF) as well as the two remaining TGFβ isoforms: TGFβ2 and TGFβ3 (Assoian et al.,
1983; Barrientos et al., 2008; Kingsley 1994; Rahimi and Leof 2007). The three TGFβ
isoforms are predominantly expressed by macrophages, endothelial, fibroblasts and
epithelial cells at the site of the injured skin (Barrientos et al., 2008; Rahimi and Leof,
2007). Both covalent and non-covalent interactions of mature TGFβ polypeptide with the
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latency associated peptide (LAP) or other latent TGFβ-binding proteins renders it
inactive (Leask 2008; Munger et al., 1997; Rahimi and Leof, 2007). Upon cellular
secretion, these latent TGFβ-binding proteins and/or LAP are removed by proteolysis,
allowing for the formation of an active 25kDa TGFβ dimer which initiates signaling
responses by interacting with the type II/type I (activin receptor-like kinase, ALK)/TGFβ
heteromeric receptor complex comprised of one of the five and seven distinct receptor
types respectively (Leask 2008; Rahimi and Leof, 2007). Type III (betaglycan) and type
V (IGFBP-3R/LRP-1) receptors may be further utilized in conjunction to the type I and
type II receptor activation (Blobe et al., 2001; Eickelberg et al., 2002; Huang et al., 2003;
Leal et al., 1997, 1999; Liu et al., 1994, 1997; O’Grady et al., 1991, 1992). ALK5
however is the most frequently utilized TGFβ type I receptor in fibroblast cells (Leask,
2008; Rahimi and Leof, 2007).
TGFβ1 participates in all stages of the physiological wound healing with
increases in its expression shortly after the onset of injury (Barrientos et al., 2008).
During the remodeling phase of wound healing, increases in the expression of tissue
inhibitor of metalloproteinases (TIMPs), collagen type I and III as well as decreases in
the expression of matrix metalloproteinases (MMP) MMP-1, MMP-3, and MMP-9 are
mediated by TGFβ1 signaling (Barrientos et al., 2008). Additional responses include
facilitation of wound contraction and closure by myofibroblasts, up-regulation of
fibronectin, collagen, fibronectin and integrin receptors and protease inhibitors as well as
recruitment of inflammatory cells to the site of injury during the earlier stages of wound
healing (Barrientos et al., 2008; Clark 1996; Mauviel et al., 1996; Meckmongkol et al.,
2007; Papakonstantinou et al., 2003; Zeng et al., 1996).
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Fibroblast activation in response to TGFβ1 involves two separate, Smaddependent and Smad-independent pathways, also known as the canonical and noncanonical pathways, respectively (Bhattacharyya et al., 2008; Leask 2006, 2008; Leask
and Abraham, 2004; Massague 1998; Mehra and Wrana, 2002; Rahimi and Leof, 2007)
(Figure 1.3).
1.5.1 Canonical TGFβ1 signaling in fibroblasts
Canonical, Smad-dependent TGFβ1 signaling in cells such as fibroblasts involves
binding of TGFβ1 ligand to the type II/type I TGFβ receptor heteromer and activation of
downstream Smad complexes, transcription factors which mediate the expression of
collagen and other pro-fibrotic genes (Leask 2008; Massague 1998; Rahimi and Leof,
2007) (Figure 1.3). The Smad family of transcriptional co-regulators includes eight
different Smad isoforms distributed among three sub-classes and utilized by different
members of the TGFβ family (Rahimi and Leof 2007). Smad 2 and 3 generally are
activated by TGFβ, Activin and Nodal members of the TGFβ superfamily; Smad 1, 5 and
8 are activated by MIS, BMP and GDF whereas the inhibitory Smads; Smad 6 and 7 act
as negative regulators of BMP and TGFβ/Activin/BMP pathways, respectively (Goumans
et al., 2002; Rahimi and Leof 2007; Trojanowska, 2009). Interestingly, the negative
regulators Smad 6 and Smad 7 are similarly transcribed via SBE activity upon TGFβ
stimulation, thus regulating its own expression and TGFβ signaling in a negative
feedback loop (Leask, 2008; Lin et al., 2003). Finally, in scleroderma fibroblasts, Smad 1
is involved in TGFβ-mediated signaling where the presence of both TGFβ and CCN2
drive Smad 1 phosphorylation and the subsequent increase in CCN2 production in a
positive feedback loop (Pannu et al., 2007; Trojanowska, 2009).
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Figure 1.3. TGFβ1 signaling in fibroblasts. Canonical and non-canonical signaling
pathways are outlined (General and Gene-Specific pathways respectively). TGFβ1
initiates signaling responses by interacting with the type II/type I TGFβ heteromeric
receptor complex, resulting in Smad3/Smad4 activation, translocation to the nucleus and
transcription of target genes by binding to the CAGA consensus sequence of Smadbinding DNA elements (SBE). Alternatively, TGFβ1 signals via integrin/syndecan4
receptors synergistically with CCN2 for additional, tissue and context specific regulation.
(Adapted with permission from Figure 2. Leask A. 2006. Scar wars: is TGFβ the
phantom menace in scleroderma? Arthritis Res Ther. 2006; 8(4): 213. Doi:
10.1186/ar1976. BioMed Central is the original publisher).
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Considering the canonical signaling pathway, TGFβ1 binds to the type II TGFβ
receptor leading to the recruitment of type I (ALK5) TGFβ1 receptor. ALK5 becomes
phosphorylated at its glycine-serine rich domain, and phosphorylates Smad 2/3 complex
at the C terminal Ser-Ser-X-Ser (SSXS) motif leading to dissociation of Smad 2/3
complex from the receptor and its subsequent association with the common mediator
Smad 4 (Derynck and Zhang, 2003; Leask 2008, Massague et al., 2005; Rahimi and Leof,
2007; Sporn and Jakowlew, 2010). Additional adaptor proteins including SARA (Smad
anchor for receptor activation), HRS/HGS (hepatocyte growth factor-regulated tyrosine
kinase substrate) and cPML may be recruited to facilitate ALK5-dependent
phosphorylation of Smads (Lin et al., 2004; Miura et al., 2000; Rahimi and Leof 2007;
Tsukazaki et al., 1998). p300/CBP co-activators may further assist in the Smaddependent gene activation and Fast-1 nuclear DNA binding protein is necessary for
Smad2 DNA interaction (Ghosh and Varga 2007; Leask, 2008; Liu et al., 1999; Zhou et
al., 1998).
Nuclear translocation of Smad 2/3-Smad 4 trimer complex and direct interaction
of Smad 3/4 with the GC rich sequences of

certain promoters as well as the

GTCT/CAGA consensus sequence of Smad-binding DNA elements (SBE) leads to
expression of collagen alpha-2(I) chain and other profibrotic genes (Bhattacharyya et al.,
2008; Derynck and Zhang, 2003; Massague et al., 2005; Rahimi and Leof, 2007)
1.5.2 Targeting canonical TGFβ1 signaling in fibrosis disease treatment
TGFβ1 signaling in fibroblasts induces both fibroblast proliferation and
differentiation into myofibroblast as well as ECM synthesis, connective tissue deposition
and contraction (Grotendorst et al., 2004; Guo et al., 2012; Leask 2008; Rahimi and Leof,
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2007). However, signaling via members of the TGFβ superfamily is known to be
involved

with

multiple

physiological

and

cellular

processes

including

immunosuppression, cell differentiation, proliferation (mesenchymal cells), migration,
growth inhibition (epithelial, endothelial, hematopoietic and neuronal cells, murine
embryonic fibroblasts) or apoptosis (Figure 1.4). (Datto et al., 1999; Grotendorst et al.,
2004; Guo et al., 2012; Leask 2008; Rahimi and Leof, 2007; Roberts et al.,1986).
Interestingly, a great number of these distinct cellular responses are mediated via the
canonical signaling pathway, often involving identical TGFβ-Smad family signaling
participants (Rahimi and Leof, 2007). However, the canonical TGFβ1 signaling pathway
does not mediate CCN2/CTGF or α-SMA expression in scleroderma fibroblasts (Chen et
al., 2006; Holmes et al, 2001). Aside from fibroblasts, TGFβ1 is also produced and
locally secreted by macrophages and other cell types and exhibits a profibrotic or
suppressive role depending on the cell type (Rahimi and Leof, 2007; Wynn 2008).
The fibrogenic phenotype arising from fibroblast exposure to TGFβ1 is nonheritable and persists only in the presence of TGFβ1 polypeptides, suggesting the
removal of “excess” TGFβ1 is sufficient to revert cells to their previous physiologic state
(Leask, 2008; McWhirte et al., 1994). TGFβ-deficient mouse models exhibit systemic
tissue necrosis, organ failure and death (Kulkarni et al., 1993). In contrast, murine models
with TGFBR1 (ALK5) deletion die in utero, probably as a result of vascular defects
incompatible with life (Carvalho et al., 2007; Larsson et al., 2001). Similarly, Smad3
knock-out murine models develop emphysema, chronic inflammation and colorectal
adenocarcinomas among other morbidities (Bonniaud et al., 2004a; Datto et al., 1999;
Yang et al., 1999; Zhu et al., 1988).
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Figure 1.4. The diverse, multifunctional, and pleiotropic effects of TGFβ. Signaling
via TGFβ affects multiple cell types and cellular processes making it difficult to target
TGFβ1 directly as a potential fibrotic disease treatment (Reproduced with permission of
Oxford University Press from Figure 2. Bujak M, Frangogiannis NG. 2007. The role of
TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res.
May 1;74(2):184-95. Epub 2006 Oct 7; Doi: 10.1016/j.cardiores.2006.10.002)
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Not surprisingly, studies that manipulate canonical TGFβ1 signaling pathways do not
provide a specific point of interference which can be applied in future therapy of fibrotic
diseases (Bonniaud et al., 2004; Denton et al., 2007; Evans, et al., 2003; Hu et al., 2003;
Kulkarni et al., 1993; Leask et at., 2008; Shull et al., 1992). Further, the use of a
recombinant human anti-TGFβ1 antibody (CAT-192) in a clinical trial for the treatment
of early-stage diffuse cutaneous systemic sclerosis resulted in adverse side-effects
including death without evidence of efficacy (Denton et al., 2007). Collectively, these
observations suggest that examining non-canonical TGFβ signaling pathways, which may
mediate specific cellular responses to TGFβ1, might be more target specific for the
treatment of fibrosis.
1.5.3 Non-canonical TGFβ1 signaling in fibroblasts
Several Smad-independent, non-canonical TGFβ1 signaling pathways have been
previously identified in fibroblasts (Leask 2008; Massague 1998; Rahimi and Leof, 2007;
Verrecchia and Mauviel, 2007; Wynn 2008; Zhang 2009). These pathways cooperate
with canonical TGFβ1 signaling, and tend to be gene and tissue specific (Figure 1.3).
Non-canonical TGFβ1 signaling can involve the MEK/ERK, p38 or JNK MAP kinase
(MAPK) pathways. For example, TGFβ-dependent activation of Ras-MEK1-ERK1/2Elk-1 occurs via heparan sulfate-containing proteoglycan (HSPG) syndecan 4 as a coreceptor (Barrientos et al., 2008; Chen et al., 2005; Massague et al., 2005; Verrecchia and
Mauviel, 2007; Zhang 2009). Additional non-canonical signaling may involve Rho-like
GTPase signaling pathways as well as phosphatidylinositol-3-kinase (PI3K)/AKT
pathways (Zhang 2009). One example of the latter includes TGFβ-mediated activation of
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p21 activated kinase 2 (PAK2) and Akt via PI3K intermediate (also an independent
regulator) in fibroblasts (Rahimi and Leof, 2007; Wilkes et al., 2003; 2005).

1.6 TAK1
TGF-β-activated kinase 1 (TAK1) mediates the ability of TGFβ1 to activate the
p38 and JNK MAP kinase cascades (Guo et al., 2012; Shim et al., 2005, Shi-Wen et al.,
2009; Yamaguchi et al., 1995; Yamashita et al., 2008). This protein belongs to the
mitogen-activated protein kinase kinase kinase (MAPKKK) family and was first
identified in 1995 based on a screen of a murine cell line cDNA expression library (Shim
et al., 2005; Yamaguchi et al., 1995). Activation of ectopic TAK1 in the MC3T3-E1 cell
line following TGFβ treatment implicated this kinase in TGFβ1-mediated MAPK
signaling, and established its name as TGFβ-activated kinase 1 (Yamaguchi et al., 1995).
In humans, the 606 amino acid TAK1 protein sequence contains a unique 300
amino acid C terminal region, as well as a putative N terminal domain resembling that of
Raf-1 and MEKK kinases (30% identity) (Wu et al., 2013; Yamaguchi et al., 1995). An
ATP-driven protein kinase catalytic region lies at the junction between the two domains
(Wu et al., 2013).
TAK1-mediated signaling is activated in a number of cellular responses,
including inflammation, apoptosis as well as certain cancers (Sakurai, 2012; Shim et al.,
2005; Yamashita et al., 2008). Aside from TGFβ signaling, tumor necrosis factor-α
(TNF-α), interleukin 1-β (IL-1β) and Toll-Like receptor ligands use TAK1 as an
intermediate in the activation of JNK/p38 and I-kappa B kinases (IKK), as well as
downstream transcription factors including Activator protein 1 (AP-1) and NF-kappaB
(Guo et al., 2012; Shim et al., 2005; Shi-wen et al., 2009; Wang et al., 1997,2001;
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Yamashita et al., 2008). TAK1 is therefore an important mediator of inflammatory
responses (via NF-kappaB and AP-1 activation) (Shim et al., 2005; Shi-wen et al., 2009;
Yamashita, et al., 2008).
TAK1 has organ-specific effects. For example, TAK1 is essential for hepatic
homeostasis. Loss of TAK1 from the liver using hepatocyte-specific Tak1-deficient
(Tak1ΔHEP) mice resulted in inflammation, spontaneous hepatocyte death and
perisinusoidal fibrosis developing at one month of age and eventually resulting in cancer
(Inokuchi et al., 2010). Interestingly, tamoxifen-driven, global TAK1 deletion in mice
conferred resistance to the development of renal fibrosis upon unilateral ureteric
obstruction, resulting in reduced myofibroblast counts, collagen and pro-fibrotic gene
expression due to abolished IL-1, TNF-α-induced JNK, p38, and NF-κB signaling
attributed to TAK1 loss (Ma et al., 2011).
1.6.1 TAK1- mediated non-canonical TGFβ1 signaling in fibroblasts
In human and mouse fibroblasts, TGFβ1 activation of TAK1 results in the
phosphorylation of stress-activated MAP kinase members JNK (via MKK4 intermediate)
and Stress Activated Kinase p38 (via MKK6 or MKK3 intermediates) (Guo et al., 2012;
Liu et al., 2007; Lovgren et al., 2011; Rahimi and Leof, 2007; Shibuya, et al., 1996;
Thannickal et al., 2003; Wang et al., 1997, 2001; Yamaguchi et al., 1995; Yamashita et
al., 2008). TGFβ receptor-dependent phosphorylation of TAK1 is also known to involve
HPK1 and/or TAB1/TAB2 adaptor proteins (Rahimi and Leof 2007; Shibuya et al., 1996;
Wang, et al., 1997, 2001; Yamashita et al., 2008). Interestingly, TAB2 was found to be
dispensable in regards to TGFβ induced gene expression and TAK1-mediated JNK
signaling (Shim, et al., 2005). A study by Yamashita and colleagues in 2008 also
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identified TNF-receptor-associated factor 6 (TRAF6) ubiquitin ligase as a direct link
between the TGFβ receptor complex and TAK1, where the activated receptor complex
leads to K63 polyubiquitination of TRAF6 which then mediates TAK1 activation by a yet
unknown mechanism, possibly including TAK1/TAB2 complex formation and/or
activation (Shim et al., 2005; Wang, et al., 2001; Yamashita et al., 2008). Activation of
TAK1 through TGFβ1 receptor signaling is further thought to involve focal adhesion
kinase: phosphorylation of TAK1 upon TGFβ1 stimulation was reduced either by pretreatment of wild-type fibroblasts with the FAK/Src inhibitor PP2, or in fibroblasts with
FAK deletion (Shi-wen et al., 2009). Canonical, Smad-mediated signaling was unaltered
upon TAK1 deletion, consistent with the idea that TAK1 is a mediator of non-canonical
TGFβ1 signaling (Shi-wen et al., 2009; Shim et al., 2005; Yamashita et al., 2008).
1.6.2 Role of TAK1 in dermal homeostasis and wound repair
The TAK1-JNK/p38 pathway has been previously shown to play an important
role in adhesive, migratory, proliferative and contractile responses of dermal fibroblasts,
as well as in fibroblast to myofibroblast differentiation in response to TGFβ1 (Guo et al.,
2012). Much of what is known about the role of TAK1 in fibrosis comes from studies of
dermal fibroblasts and cutaneous disease. Fibroblasts isolated from the skin of
scleroderma patients exhibited elevated levels of constitutively active TAK1 protein (Shiwen et al., 2009). Decreased expression of collagen and other pro-fibrotic genes in the
skin was observed in the fibroblast-specific TAK1 knock-out (TAK1-KO) mouse model,
which also showed reduced skin thickness, delayed wound closure and decreased
collagen deposition (Guo et al., 2012). TAK1-KO dermal fibroblasts exhibited reduced
levels of proliferation (Guo et al., 2012). Inhibition of TAK1 in human skin fibroblasts
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using (5Z)-7-Oxozeaenol, a TAK1 selective inhibitor, also led to reduced expression of ~
66% of pro-fibrotic genes following in vitro treatment with TGFβ1 (Guo et at., 2012;
Ninomiya-Tsuji et al., 2003). Thus, previous studies suggest that TAK1 plays an
important role in maintaining dermal homeostasis as well as in mediating some of the
pathways expected to play a role in fibrotic disease onset and progression.
1.6.3 (5Z)-7-Oxozeaenol: a TAK1 selective inhibitor
(5Z)-7-Oxozeaenol (also known as C 292, F 152, FR148083, L 783279, LLZ1640-2) is a natural resorcyclic lactone first isolated in 1978 from an unidentified
fungus and later in 2003 from the f6024 fungal strain culture broth in a quest for
identifying an inhibitor of TAK1 to combat pro-inflammatory signaling (Ellestad et al.,
1978; Murray, 2009; Ninomiya-Tsuji et al., 2003). (5Z)-7-Oxozeaenol acts at the level of
the ATP binding site of TAK1 to irreversibly inhibit TAK1 catalytic activity by forming
a covalent bond with the C8’ of the cis-enone and Cys174 residue of TAK1 (NinomiyaTsuji et al., 2003; Wu et al., 2013). A TAK1-specific IC50 of 8 nM and 65 nM was
previously reported based on the in vitro and in vivo kinase assays respectively
(Ninomiya-Tsuji et al., 2003). In comparison, the in vitro IC50 for MEKK1 was 268 nM
and the activities of MEKK4 (another MAPKKK family representative) and ERK were
not inhibited at 500 nM (5Z)-7-Oxozeaenol (Ninomiya-Tsuji et al., 2003). Downstream
targets of TAK1 such as JNK and p38 were also not inhibited by (5Z)-7-Oxozeaenol
(Ninomiya-Tsuji et al., 2003).

1.7 TGFβ1 signaling: role of CCN2
In dermal and gingival fibroblasts, TGFβ1 potently induces the expression of the
pro-fibrotic marker and mediator CCN2 (connective tissue growth factor), a member of
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the CCN family of matricellular proteins (named for the first three members: cyr61, ctgf
and nov) (Black and Trackman 2008; Brigstock 2010; Leask 2008; Leask et al, 2009;
Thompson et al., 2010). Matricellular proteins are known for their regulatory, as opposed
to structural roles in modifying responses to growth factors and the microenvironment
(Leask 2013a, 2013b.) Aside from CCN2, the CCN family in humans is comprised of 5
other members classified together based on a predicted four-modular structure and
presence of N-terminal secretory signal: cysteine-rich 61 (Cyr61/CCN1), nephroblastoma
over-expressed (Nov/CCN3), and the Wnt-induced secreted proteins (WISP-1, CCN4), -2
(WISP-2, CCN5) and 3 (WISP-3, CCN6) (Brigstock, 2003). CCN2 was identified over
20 years ago by Bradham and others as a 38-kDa, cysteine-rich protein secreted in
endothelial cell culture capable of inducing fibroblast chemotaxis and cell division
(Bradham et al., 1991; Leask 2013a, 2013b). The mature CCN2 protein is comprised of
four modular domains: an insulin-like growth factor binding protein (IGFBP) domain
(module I), a Von Willebrand factor domain (module II), a thrombospondin-homology
domain (module III), cysteine knot heparin-binding domain (module IV) and possibly an
un-cleaved signal peptide sequence. A “hinge region” between modules II and III allows
for differential cleavage and fragmentation of the CCN2 protein which may have an
effect on CCN2 function (Figure 1.5) (Bork 1993; Brigstock, 2003; Leask 2013a, 2013b;
Perbal 2004).
1.7.1 CCN2 mediates wound healing and fibrosis
As observed with TGFβ1 expression, the levels of CCN2 increase rapidly
following injury, and both the proliferative and remodeling phases of wound healing are
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Figure 1.5. CCN2 protein structure (signal peptide and Modules I-IV) and signaling
in fibroblasts. CCN2 binds integrins and heparan sulfate proteoglycan (HSPG) receptors
on fibroblast surface. Binding of fibronectin and synergistic binding of TGFβ1 by CCN2
transduces the signals from the ECM inside the fibroblast. (Adapted from: Figure 2.
Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling
modulators emerge from the bunker. J Cell Sci. 2006 Dec 1;119 (Pt 23):4803-10.
Doi: 10.1242/jcs.03270; jcs.biologists.org)
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regulated by CCN2-mediated response (Barrientos, et al., 2008). CCN2 expression is
elevated in fibrotic conditions affecting all organs including atherosclerosis, scleroderma,
keloids, hypertrophic scars, gingival hyperplasia, muscular dystrophy, Dupuytren’s
disease, idiopathic pulmonary fibrosis as well as diabetic retinopathy and nephropathy
(Barrientos et al., 2008; Holmes et al., 2001; Kantarci et al., 2006; Leask 2013a, 2013b;
Leask et al., 2009; Ponticos et al., 2009; Sonnylal et al., 2010; Thompson et al., 2010;
Uzel et al., 2001). Elevated levels of CCN2 expression also serve as indicators of the
severity of systemic fibrosis and correlate well with the presence of myofibroblasts and
elevated ECM production by fibroblasts (Leask and Abraham, 2006; Ponticos et al.,
2009). Loss of CCN2 expression in fibroblasts results in resistance to skin fibrosis,
suggestive of the requirement of CCN2 for the development of skin fibrosis in vivo (Liu
et al., 2011). CCN2 expression is induced by TGFβ1, yet it also behaves as a co-factor
promoting TGFβ1-mediated ECM adhesion and fibrogenesis (Mori et al., 1998; Shi-wen
et al., 2006; Wang et al., 2011) (Figure 1.5). CCN2 promotes fibroblast adhesion via
association with HSPG and integrins, the specific identity of which tend to be cell type
specific (Leask and Abraham, 2006). CCN2 potentiates other responses including:
fibroblast growth, proliferation and chemotaxis, increase expression and deposition of
collagen, fibronectin and other matrix proteins, up-regulation of integrin receptors,
angiogenesis, endothelial migration, adhesion and proliferation (Barrientos et al., 2008;
Holmes et al., 2001; Krieg et al., 2007; Leask 2008, 2013a, 2013b; Ponticos et al., 2009).
The heparin binding domain also mediates the ability of CCN2 to bind low-density
lipoprotein receptor-related protein 1 (LRP1) (Leask and Abraham, 2006; Segarini et al.,
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2001). Thus, understanding how CCN2 is regulated in fibroblasts is likely to yield
valuable insights into the treatment of fibroproliferative disorders.
1.8 Gingival hyperplasia
In contrast to every other adult tissue, the oral cavity does not scar in response to
injury (Egusa et al., 2010; Guo et al., 2011a, 2011b; Schor et al., 1996, Sciubba et al.,
1978). Unlike skin wounds, gingival wounds heal faster and without scarring, although
the stages of the healing process and their sequence remain similar between the two tissue
types (Egusa et al., 2010; Guo et al., 2011a, 2011b; Schor et al., 1996, Sciubba et al.,
1978; Wikesjo et al., 1992). One example of a fibrotic condition in the oral cavity is
gingival hyperplasia, characterized by an excessive gingival overgrowth in susceptible
patients as a side effect to antiepileptic medications, calcium channel blockers and
immunosuppressant drugs or as a result of other factors including disease and genetic
predisposition (Clocheret et al., 2003; Nakib and Ashrafi, 2011) (Figure 1.6). In contrast
to the typical, hyper-contractile response observed in fibrotic diseases, gingival
hyperplasia is characterized by a hyper-proliferative response, likely due to the inherent
tissue-specific differences in resident fibroblast cells (Guo et al., 2011a, 2011b). In vivo,
fibrotic responses in the oral cavity are not generally characterized by the presence of
myofibroblasts but instead are characterized by hyper-proliferation of fibroblast cells
(Bitu et al., 2006; Damasceno et al., 2012; Sobral et al., 2010). This feature could arise
due to a reduced or altered sensitivity of gingival fibroblasts, relative to dermal
fibroblasts to mechanical strain, TGFβ1 or the use of alternative TGFβ1 signaling
pathways (Guo et al., 2011a,b).
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Figure 1.6. Hereditary gingival overgrowth. Unlike skin, gingiva does not scar. In
contrast to the hyper-contractile fibrotic disease presentation associated with
myofibroblast differentiation, gingival hyperplasia is characterized by a fibroblast
proliferation and relative lack of myofibroblasts in the oral cavity. Taken directly from:
Fig. 1b. Orthodontic records after periodontal surgery. Clocheret K1, Dekeyser C, Carels
C, Willems G., ‘Idiopathic gingival hyperplasia and orthodontic treatment: a case
report.’, Journal of Orthodontics, 2003 Mar;30(1):13-9. http://jorthod.maneyjournals.org/
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1.9 Human gingival fibroblasts vs dermal fibroblasts. What do we know?
Studies analyzing transcriptional and functional differences among fibroblasts
resident in various tissue niches are gaining importance with increasing evidence of intertissue fibroblast heterogeneity (Chang et al., 2002; Chipev et al., 2002; Ebisawa et al.,
2011; Guo et al., 2011a, 2011b; Yasuda et al., 2006). Although dermal and gingival
fibroblasts appear to be morphologically identical in culture, differences at the level of
gene expression have been previously reported (Ebisawa et al., 2011; Guo et al., 2011a,
2011b). A study by Ebisawa and colleagues (2011) recently investigated differential gene
expression in primary cultures (passages 4-5) of human gingival and dermal fibroblasts
using DNA microarray, to gain a better insight into the existing functional differences of
the two cell types (Ebisawa et al., 2011). From the 5284 analyzed genes, the expression
of 5% (278) of genes was found to be significantly different; 114 genes were only
expressed in dermal fibroblasts whereas 164 genes were only expression in gingival
fibroblasts (Ebisawa et al., 2011). Differences in the extracellular matrix-related genes,
oxidoreductase activity-related genes, cytokine activity-related genes and growth factorrelated genes were prominent between the two cell types (Ebisawa et al., 2011). A similar
study using DNA microarray gene expression profiling identified close to 800 genes
which were found to be enriched in the human dermal fibroblast cell line as compared to
human gingival fibroblasts (Guo et al., 2011b). These included the pro-adhesive genes
such as paxillin, integrins α2 and α4 and FAK (Guo, et al., 2011b). In a different study,
expression of integrins β3, a11, α2 and α5 exhibited 15-, 10-, 5- and 5- fold increased
expression, respectively, in human dermal fibroblasts as compared to human gingival
fibroblasts (Palaiologou et al., 2001). In contrast, expression of integrin subunit α3, α8
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and β6 was found to be increased in gingival fibroblasts as compared to dermal
fibroblasts by 50-, 15- and 5- fold, respectively (Palaiologou et al., 2001). Interestingly,
no correlation was found between the expression pattern of heterodimeric integrin
receptors and the fibroblast attachment profile to ECM (Palaiologou, et al., 2001).
1.9.1 A comparison between gingival and dermal fibroblasts: differences in function
The relative differences in wound healing and fibrotic responses between skin and
gingiva may be further precipitated when fibroblasts are subjected to the wound
healing/fibrogenic contexts and fibrogenic stimuli. Three dimensional fibrin lattices have
been used to culture fibroblasts to mimic cellular environment during the early phases of
wound healing, including inflammation and formation of fibrin clot (Bell et al., 1983;
Lorimier et al., 1996, 1998; Niewiaro et al., 1972). Gingival fibroblasts seeded onto a
fibrin lattice resulted in a rapid retraction and lysis of the lattice and complete
disappearance after one week, suggesting a higher degree of fibrinolytic activity in
gingival fibroblast as compared to dermal fibroblasts (Lorimier et al., 1998).
Interestingly, the expression of matrix metalloproteinases (MMP2, MMP9) and tissue
inhibitors of metalloproteinases (TIMP2) was more rapid and robust by the gingival
fibroblast, suggesting a greater capacity of matrix remodeling by the gingival as
compared to dermal fibroblasts (Chaussain Miller et al., 2002)
Further, the shielding properties normally exhibited by the ECM matrix as a
protective barrier from the external environment and mechanical forces may be lost as a
result of injury and are thus thought to expose the fibroblasts to the forces of mechanical
tension, followed by the differential adaptation of the two cell types to the new, “stress
unshielded” environment, likely promoting fibroblast to myofibroblast differentiation
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(Guo et al., 2011a; 2011b, Hinz and Gabbiani, 2003; Kessler et al., 2001). Mechanical
strain induced a number of pro-proliferative genes (CDC6, cdk6) as well as TGFβ1, ET-1
(albeit at relatively low levels) and CCN2 gene expression in donor-derived human
gingival fibroblasts whereas potent induction of collagen type I and αSMA did not occur
(Guo et al., 2011a; 2011b). Further, the fibrotic gene cluster was not identified using
microarray analysis of the gingival fibroblasts post 72 hour strain while genetic cluster
involved in cellular proliferation (cdc6,cdk6) was induced in response to strain,
consistent with the notion that gingiva possess a hyper-proliferative as opposed to hypercontractile fibrotic response (Guo et al., 2011a; 2011b).
Similarly to strain, a six hour induction of human dermal fibroblasts with TGFβ1
ligand (4ng/ml) potently increased the levels of CCN2, collagen I and α-SMA mRNAs,
whereas only CCN2 expression was induced in human gingival fibroblasts in response to
TGFβ1 albeit to a lesser extent than in dermal fibroblasts (Guo et al 2011a). The effect
was attributed to the fact that gingival fibroblasts possess reduced ET-1 mRNA and
protein as compared to human dermal fibroblasts; the difference in the αSMA and
collagen I induction between the two cell types was rescued upon co-incubation of
gingival fibroblasts with both TGFβ and ET-1 (Guo, et al., 2011a).
Further of interest is the observation that gingival wounds heal faster and with
less scar formation as compared to skin wounds, although the stages of the healing
process and their sequence remain similar between the two tissues (Egusa, et al., 2010;
Guo et al., 2011a, 2011b; Schor, et al., 1996, Wikesjo, et al., 1992). Therefore it is
possible that TGFβ1 signals through different pathways in dermal vs gingival fibroblasts.
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In this regard, the role of non-canonical TGFβ1 signaling in gingival fibroblast remains
to be explored. (Guo et al, 2011a, 2011b).

1.10 Rationale, Objectives and Hypothesis
Canonical TGFβ1 signaling is involved in multiple intracellular signaling
pathways and in a number of physiological and cellular processes (Datto et al., 1999;
Grotendorst et al., 2004; Guo et al., 2012; Leask 2008; Mehra and Wrana 2002; Rahimi
and Leof, 2007; Roberts et al., 1986; Yamashita et al., 2008). Thus, broad targeting of the
TGFβ1- mediated pathways may lead to deleterious side effects; previous studies which
tried to interfere with the downstream targets of the canonical TGFβ1 signaling yielded
no promising results (Bonniaud et al., 2004a; Datto et al., 1999; Evans et al., 2003;
Grotendorst, et al., 2004; Hu et al., 2003; Leask et at., 2008; Mehra and Wrana, 2002;
Rahimi and Leof, 2007; Roberts et al., 1986; Wang, et al., 1997; Yamashita, et al.,
2008). Indeed, the use of CAT-192, a recombinant human anti-TGFβ1 antibody, led to
adverse side-effects including death and no evidence of efficacy in the clinical trials of
early-stage diffuse cutaneous systemic sclerosis treatment (Denton et al., 2007). Previous
studies have identified the non-canonical, TAK1/JNK mediated signaling to play a role in
physiological and pathological fibroblast function in the skin (Guo et al., 2012).
Targeting the non-canonical pathways may thus represent a new and promising field in
the development of novel therapeutics for the fibrotic disease treatment.
The involvement of non-canonical, TAK1-mediated signaling in TGFβ1 driven,
pro-fibrotic or hyper-proliferative responses in gingival fibroblasts has not been
previously examined. Whether TAK1 mediates TGFβ1-driven fibro-proliferative
responses in gingival fibroblasts is also unknown. In addition, the role of TAK1-mediated
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CCN2 expression in gingival fibroblasts has not been previously investigated, although
the known involvement of CCN2 signaling in fibrotic conditions including gingival
hyperplasia render CCN2 as a promising target for future anti-fibrotic therapies (Black
and Trackman, 2008; Blom et al., 2002). Therefore, my overall objective was to use the
TAK1 selective inhibitor (5Z)-7-Oxozeaenol to assess the role of TAK1 in human
gingival fibroblast responses to TGFβ1. My hypothesis was that TAK1 mediates the
ability of TGFβ1 to a) induce CCN2 expression and b) induce transcriptional responses in
gingival fibroblasts. My thesis described data supporting the hypothesis that targeting the
non-canonical TAK-mediated TGFβ1 signaling pathway may be useful to combat
gingival hyperplasia in the future.
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2. Materials and Methods
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2.1 Human gingival fibroblast culture
Gingival fibroblasts from one healthy human donor were used for this study and
are described elsewhere (Thompson et al., 2010). Cells were grown as monolayers in
high glucose DMEM growth media (Gibco) supplemented with 10% FBS (Gibco) and
1% Antibiotic-Antimycotic mix (Gibco) at 37°C, 5% CO2 (SANYO Scientific laboratory
incubator). At 40 -60% confluence, cultures were serum starved (low glucose DMEM
growth media supplemented with 0.5% FBS and 1% Antibiotic-Antimycotic antibiotic
mix) overnight and pre-treated with DMSO (vehicle control; Sigma-Aldrich) or 400 nM
(5Z)-7-Oxozeaenol (Tocris) for 45 minutes followed by treatment with or without
recombinant human TGFβ1 (4 ng/ml; 90 pM; R&D systems) for 6, 24, 48 and 72 hours
as indicated (Guo et al., 2012). Cultures of passages 8 through 10 were utilized for this
study.

2.2 RNA extraction
Cell monolayers were subjected to the total RNA extraction adapting the Trizol
method as described previously (Ambion, Life-Technologies; Chomczynski and Sacchi,
1987). Briefly, cell monolayers were lysed in TRIzol® (Ambion, Life Technologies)
followed by the addition of 0.2 volumes chloroform (Sigma-Aldrich). The samples were
centrifuged to allow for phase separation and ~70% of the supernatant was collected.
Isopropanol (Sigma-Aldrich) was added in a 1:1 isopropanol to supernatant fraction
volume ratio respectively and the samples were centrifuged to pellet the precipitated
RNA. The latter was washed with 80% ethanol (GreenField Ethanol Inc), pelleted, airdried and re-dissolved in nuclease-free water (Thermo Fisher Scientific). The
concentration and integrity of the extracted RNA sample was measured using the Nucleic
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Acid, Nanodrop program (Thermo) and RNA quality was assessed using an Agilent 2100
Bioanalyzer (Agilent Technologies Inc.) and RNA 6000 Nano kit (Caliper Life Sciences).
The latter procedure was conducted at the London Regional Genomics Centre (David
Carter, Robarts Research Institute, London, Ontario, Canada).

2.3 RT-qPCR analysis
Extracted RNA samples (50 ng) were reversed transcribed and amplified using
TaqMan Human gene Expression assays (Applied Biosystems) in a 15-μL reaction
containing qScript™ XLT One-Step RT-qPCR ToughMix (Quanta Biosciences),
TaqMan Human gene specific target primers (Applied Biosystems) and FAM (6carboxyfluroscein labeled) gene specific TaqMan MGB probes (Assays on demand;
Applied Biosystems) as per previously established protocols (Thompson et al., 2010).
ViiA™ 7 Real-Time PCR System and ViiA™ 7 Software were used for detection and
analysis of the amplified signal according to manufacturer’s instructions (Applied
Biosystems). Relative gene expression was obtained for CCN2, IL11, PDGFA, EDN1,
JUNB, IGFBP3 and SERPINE1 genes and standardized to the 18S expression as the
internal control using the ΔΔCt method (Livak et al., 2001). Triplicate samples were
examined and the experiments were repeated on three independent occasions with
averages +/- SEM (N=3) calculated. Two-Way ANOVA and Tukey's Post Hoc analysis
were used for statistical analysis (GraphPad Prism software).

2.4 Genome-wide expression profiling
All sample labeling and GeneChip processing was conducted by the London
Regional Genomics Centre (David Carter, Robarts Research Institute, London, Ontario,
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Canada) for two independent HGF treatment sets (DMSO, TGFβ1, (5Z)-7-Oxo as well as
TGFβ1 + (5Z)-7-Oxo treated; Passages 8 and 9). Briefly, single stranded complementary
DNA (sscDNA) was prepared from 200 ng of total RNA as per the Ambion WT
Expression Kit for Affymetrix GeneChip Whole Transcript WT Expression Arrays and
the Affymetrix GeneChip WT Terminal Labeling kit and Hybridization User Manual.
Total RNA was first converted to cDNA, followed by in vitro transcription to make
cRNA. Five and a half micrograms of single stranded cDNA was synthesized, end
labeled and hybridized, for 16 hours at 45°C, to Human Gene 1.0 ST arrays (Affymetrix).
All liquid handling steps were performed by a GeneChip Fluidics Station 450 and
GeneChips were scanned with the GeneChip Scanner 3000 7G using Command Console
v1.1 (Affymetrix). Probe level (.CEL file) data was generated using Affymetrix
Command Console v1.1. Probes were summarized to gene level data in Partek Genomics
Suite v6.6 (Partek) using the RMA algorithm (Irizarry et al., 2003). Partek was used to
determine gene level ANOVA p-values and fold changes. Gene lists were created using
a filter of 1.7 fold change and p-value of < 0.05. Genes showing 1.7 fold induction and
1.7 fold down regulation in the TGFβ1 + (5Z)-7-Oxozeaenol group as compared to the
(5Z)-7-Oxozeaenol group alone were subtracted from the pool of TGFβ1 (1.7 fold)
induced genes as compared to the DMSO control group. This resulting pool of (5Z)-7Oxozeaenol-dependent mRNAs with over 1.7 fold induction in response to TGFβ-1
treatment was subject to Functional Annotation clustering (DAVID Functional
Annotation Software). The 1.7 fold cut-off value was selected based on the previous
analysis of TGFβ1 treated human dermal fibroblasts carried out in a separate study in our
lab (Guo et al., 2012).
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2.5 Western Blot analysis
Cells were serum starved overnight, pre-treated with (5Z)-7-Oxozeaenol or
DMSO followed by the treatment with or without recombinant human TGFβ1 as
described previously. Cell monolayers were lysed 24 hours later in RIPA buffer (100 mM
Tris HCl, pH 7.4; 150 mM NaCl; 1% NP40; 0.1% SDS; 5 mM EDTA) supplemented
with protease inhibitor mini complete tablet (Roche) and sonicated twice for 5 sec with
concomitant 10 min incubation periods on ice. Samples were then centrifuged at 13,700 x
g for 12 min at 4°C and the supernatant fraction collected. Total protein concentration of
the lysates was established using the BCA assay microplate procedure (Pierce) based on
the standard curve absorption values and the total protein content was equalized to 50 μg
among all samples with Laemmli (63 mM Tris-Cl, pH 6.8; 10% glycerol; 5% βmercaptoethanol, 2% SDS, 0.01% bromophenol blue) and RIPA Lysis buffers as per
manufacturer’s instructions (Pierce). The lysates were then incubated at 99°C for 5 min
and loaded onto the 10% SDS gel matrix subjected to 130 V for ~2 hours in the
presence of 1X Running buffer (5 mM Tris; 40 mM Glycine; 0.02% SDS) required for
protein separation. The 10% SDS gel was transferred onto nitrocellulose membrane
using iBlot dry transfer kit and iBlot dry transfer machine (Invitrogen). The membranes
were incubated for 1 hour in Blocking buffer solution (50 mM Tris, 150 mM NaCl;
0.05% Tween®-20; 5% skim milk) followed by the addition of CCN2 (L-20) goat
polyclonal primary antibody (Santa Cruz Biotechnology; sc-14939) in a 1:250 dilution
and subsequent overnight incubation at 4°C. The following day, membranes were washed
three times in TBST buffer (50 mM Tris, 150 mM NaCl; 0.05% Tween®-20) at room
temperature for 10 min. Specific anti-goat secondary HRP conjugate polyclonal antibody
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(Jackson Immunoresearch, Cat. 705-036-147) was added to the membrane in a 1:2000
dilution in the blocking buffer and incubated for one hour at room temperature. Washing
procedure was repeated and membranes imaged on X-ray film (Kodak) with the use of
Chemiluminescent Substance (1:1 Lumino/Enhancer solution to Stable Peroxide Solution
ratio; Thermo Scientific; Department of Dentistry, University of Western Ontario).
Membranes were then washed in TBST and stripped with the Restore western blot
stripping buffered (Thermo) for 20 min at room temperature, blocked and re-probed with
β-actin mouse monoclonal primary antibody (Sigma, A1978-200UL; 1:8000 dilution)
overnight at 4°C in TBST. Appropriate anti-mouse HRP conjugated antibody was chosen
(Jackson Immunoresearch; 1:8000 dilution) to obtain β-actin signal intensity at the 1.5
sec exposure time period. Densitometry measures for CCN2 band intensities for TGFβ1
and TGFβ1 + (5Z)-7-Oxozeaenol treatment groups were obtained using ImageJ program
(NIH) and standardized to the respective β-actin levels. Student’s t-test was used for
statistical analysis (GraphPad Prism software).

2.6 Indirect immunofluorescence procedure
Cells cultured on glass coverslips (VWR) were fixed in 4% paraformaldehyde in
PBS (10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl; pH 7.4), permeabilized with
0.2% TritonX100 (Sigma-Aldrich) in PBS and blocked with 5% Donkey serum in PBST
(10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl ,0.05% Tween® 20; pH 7.4) for
30 min at room temperature followed by the addition of CCN2 (L-20) goat polyclonal
antibody (Santa Cruz Biotechnology; sc-14939) in 1:100 dilution. Following one hour
incubation at room temperature, the samples were washed three times with PBS for 5 min
and incubated with a DyLight 594 anti-goat IgG secondary antibody in a 1:1000 dilution
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in 5% Donkey serum in PBST for 45 min at room temperature in the dark (Jackson
ImmunoResearch Laboratories; Cat. 705-516-147). The coverslips were washed with
PBS (three times for 5 min) and mounted on the slides using VECTASHIELD ®
Mounting Media (Vector Laboratories). Images were taken with a Zeiss Axiophot
microscope using Northern Eclipse software. Total fluorescence intensity was obtained
using the Northern Eclipse software for each individual image and divided by the
representative cell number obtained by using DAPI stain as a guide for the number of
cells captured in each individual image. Relative fluorescence intensity ratio was further
obtained using DMSO treatment group as a standard. Two-Way ANOVA and Tukey's
Post Hoc analysis were used for statistical analysis (GraphPad Prism software).

2.7 Proliferation Assay
For the cell proliferation assay, cells were seeded in 96-well plates (Greiner BioOne) at 500 cells per well and cultured for one day in 10% FBS, high glucose DMEM
media as described above. A “no-cell control” group was also incorporated involving
only the addition of cell culture media. Cultures were then serum starved (0.5% FBS, low
glucose DMEM) overnight and were pre-treated with DMSO (vehicle control) or 400 nM
(5Z)-7-Oxozeaenol for 45 minutes followed by subsequent treatment with or without
recombinant human TGFβ1 (4 ng/m; 90 pM) in quadruplicates. BrdU reagent (1X; Cell
Signalling) was also added to all treatment groups at this time. The latter incorporates
into the newly synthesised DNA. Cultures were incubated for zero, 24, 48 and 72 hours
and subject to the BrdU proliferation assay using a kit as per manufacturer’s instructions
(Cell Signalling). Briefly, cells were fixed and DNA denatured using a fixing/denaturing
solution. Primary BrdU mouse mAb was added to bind the incorporated BrdU followed
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by the addition of an anti-mouse IgG, HRP-linked antibody to bind the primary antibody.
HRP substrate TMB was added to develop color and the plate incubated for 30 min
followed by the addition of Stop solution. Proliferation was then determined from the
absorbance values reading obtained at 450 nm (iMark™ microplate absorbance reader)
and this corresponds to the quantity of BrdU incorporated into the cells. The raw data was
processed for the detection and removal of outliers using the Interquartile Range
calculation and was further noise adjusted by subtracting the average “no-cell control”
reading from each individual well. Experiments were performed thrice.

2.8 Statistical Analysis
Student’s t-test, two-way ANOVA and Tukey's Post Hoc analysis were used for
statistical analysis (GraphPad Prism software) where applicable.
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3. Results
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3.1 TAK1 mediates TGFβ1- induced gingival fibroblast CCN2 expression
CCN2 is a matricellular protein of the CCN family implicated in fibroproliferative responses in fibroblasts (Chen and Lau, 2009; Leask and Abraham, 2006).
CCN2 is up-regulated in response to TGFβ1 via canonical and non-canonical signaling
pathways and acts to enhance TGFβ1-mediated fibroblast signaling responses
(Grotendorst et al., 2006; Holmes et al., 2001; Mori et al., 1998; Thompson et al., 2010;
Wang et al., 2011). Moreover, CCN2 is required for skin fibrosis in vivo (Liu et al.,
2011). In dermal fibroblasts, TGFβ1 induces CCN2 expression via TAK1 (Guo et al.,
2012). I thus investigated whether TAK1 mediates TGFβ1-induced CCN2 mRNA and
protein expression using Real Time PCR analysis as well as Western blot and indirect
immunofluorescence analysis, respectively. At the transcriptional level, TGFβ1
significantly up-regulated CCN2 expression in gingival fibroblasts resulting in 7- fold
increase in CCN2 mRNA levels similar to previously published results (Figure 3.1)
(Thompson et al., 2010). Pre-treatment of gingival fibroblasts with (5Z)-7-Oxozeaenol, a
TAK1 selective inhibitor (Ninomiya-Tsuji et al., 2003) 45 minutes prior to the addition of
TGFβ1 resulted in a significant reduction of TGFβ1-induced CCN2 mRNA expression
(Figure 3.1). Similar results were seen when protein expression was examined. CCN2
protein levels were not readily detectable in unstimulated gingival fibroblasts using
Western blot and indirect immunofluorescence analyses as anticipated from previously
published data reporting low baseline CCN2 expression in gingival fibroblast cells
(Thompson et al., 2010) (Figures 3.2 and 3.3).
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Figure 3.1. TAK1 mediates TGFβ1 induced CCN2 gene expression. Human gingival
fibroblasts were serum starved overnight and pre-treated with (5Z)-7-oxozeaenol (400
nM) or DMSO for 45 min followed by treatment with TGFβ1 (4 ng/ml) ligand or left
untreated. Total RNA was harvested six hours later and subjected to TaqMan RT-qPCR
analysis using the indicated probe/primer set. 18S RNA was used as the internal control.
Note: the relative gene expression between DMSO and (5Z)-7-oxozeaenol in the absence
of TGFβ1 was not statistically significant. (N=3; averages+/-SEM are shown; *p<0.05,
Two-Way ANOVA followed by Tukey's Post Hoc analysis).
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Figure 3.2. TAK1 mediates TGFβ1 induced CCN2 protein expression: Western blot
data. Human gingival fibroblasts were serum starved overnight and pre-treated with
(5Z)-7-oxozeaenol (400 nM) or DMSO for 45 min followed by treatment with TGFβ1
(4ng/ml) or left untreated for 24 hours. Proteins were harvested and subject to Western
blot analysis with anti-CCN2 and anti-β-actin antibodies, as indicated. Experiments were
performed on 4 separate occasions. (A) Representative blot is shown. (B) Relative fold
decrease in CCN2 expression in response to (5Z)-7-oxozeaenol pre-treatment was
calculated using densitometry for TGFβ1 induced groups (N=4, averages +/ SEM are
shown; * p<0.05; Student’s t-test)
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Figure 3.3. TAK1 mediates TGFβ1-induced CCN2 protein expression: indirect
immunofluorescence analysis. Human gingival fibroblasts were serum starved
overnight and pre-treated with (5Z)-7-oxozeaenol (400 nM) or DMSO for 45 min
followed by treatment for 24 hours with or without TGFβ1 (4 n/gml). Cells were fixed
and stained with an anti-CCN2 antibody and DyLight 594 conjugated secondary
antibody. Cells were counterstained with DAPI to detect nuclei. Experiments were
conducted four times. (A) Representative micrographs are shown. White bar represents
50 μm. (B) Total fluorescence intensity was obtained using the Northern Eclipse software
for each individual image and divided by the representative cell number obtained by
using DAPI stain as a guide for the number of cells captured in each individual image.
Relative fluorescence intensity ratios were subsequently calculated using DMSO as a
standard (N=4, averages +/ SEM are shown; * p<0.05, Two-Way ANOVA followed by
Tukey's Post Hoc analysis).
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Induction of cells with TGFβ1 increased CCN2 protein expression in both
Western blot and immunofluorescence microscopy assays while the pre-treatment with
(5Z)-7-Oxozeaenol resulted in a significant reduction of TGFβ1-induced CCN2 protein
expression paralleling the results obtained by examining CCN2 mRNA expression
(Figures 3.2 and 3.3). Indirect immunofluorescence analysis further revealed that
induction of gingival fibroblasts cells with TGFβ1 resulted in the accumulation of CCN2
in the cytoplasm, possibly Golgi apparatus as was previously reported for dermal
fibroblasts (Chen et al., 2001); this accumulation was reduced in the presence of (5Z)-7Oxozeaenol (Figure 3.3). Given that CCN2 expression is a potent marker of TGFβ’s
fibrogenic actions (Leask and Abraham, 2006) and that TGFβ1-induced CCN2
expression in a TAK1-dependent manner, I thought that TAK1 may participate in
mediating TGFβ1 fibrogenic responses in gingival fibroblasts.

3.2 Inhibition of TAK1 blocks TGFβ1-induced mRNA expression in human
gingival fibroblasts
In order to further investigate a role of TAK1 in TGFβ1 signaling in gingival
fibroblasts, cells were treated with or without TGFβ1 in the presence or absence of (5Z)7-Oxozeaenol inhibitor and subjected to gene expression profiling using GeneChip
Human Gene 1.0 ST arrays. The use of gene expression profiling at the beginning of my
study allowed me to (i) assess the extent of (5Z)-7- Oxozeaenol effect on the ability of
TGFβ1 to induce genome-wide transcription and (ii) to identify functional categories of
genes affected by TAK1 inhibition. Of the 28,869 genes provided on the Human
GeneChip Gene 1.0 ST Arrays, 147 genes were up-regulated in response to TGFβ1 (1.7
fold induction compared to DMSO control group), 139 of which were found to be
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sensitive to (5Z)-7-Oxozeaenol inhibition (Figure 3.4). These results suggested that
TAK1 mediates the majority (95%) of TGFβ1 signaling responses in gingival fibroblast
cells (Ninomiya-Tsuji et al., 2003). Functional annotation of the 139 genes included
clusters for cell cycle/proliferation as well as wound healing (including migratory)
responses which became the focus of my subsequent analysis (Tables 3.1 and 3.2
respectively).

3.3 TAK1 mediates the induction of genes involved with proliferation
Based on the expression profiling data, a proliferation cluster consisting of eight
genes was identified (Table 3.1). Endothelin 1 and the Jun-B proto-oncogene were
chosen as representative genes from this cluster based on their known involvement in
scleroderma disease and pro-fibrotic programming in response to TGFβ respectively
(Chung et al., 1996; Gervasi et al., 2012; Leask, 2008; Mauviel et al., 1993, Morelli et al,
1995; Vancheeswaran et al., 1994; Yamane et al, 1992; 1996). Endothelin 1 (END1) is a
secreted protein and a downstream target of TGFβ1 with increased levels observed in
patients with fibrosis (Abraham et al., 1997; Kawaguchi et al., 1994; Leask, 2008;
Miyauchi et al., 1992; Morelli et al, 1995; Shi-Wen et al., 2006; Vancheeswaran et al.,
1994; Yamane et al, 1992) while transcription factor Jun-B (JUNB) is induced by TGFβ1
signaling in fibroblasts, mesenchymal and epithelial cells and is an important positive
mediator of epithelial mesenchymal transition (Chung et al., 1996; Gervasi et al., 2012;
Mauviel et al., 1993, 1996). To confirm the microarray data and to establish whether the
treatment of gingival fibroblasts with TAK1 inhibitor may hinder TGFβ1- induced
proliferation at the transcriptional level, I cultured gingival fibroblasts in the presence or
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Figure 3.4. (5Z)-7-oxozeaenol inhibits TGFβ1-induced mRNA expression in human
gingival fibroblasts. Human gingival fibroblasts were serum starved overnight and pretreated with (5Z)-7-oxozeaenol (400 nM) or DMSO for 45 min followed by treatment
with TGFβ1 (4 ng/ml) ligand or left untreated. Total RNA was harvested six hours later
and subjected to gene expression profiling using GeneChip Human Gene 1.0 ST arrays
(N=2). 147 genes were up-regulated in response to TGFβ1 (1.7 fold induction compared
to DMSO control group) and 139 genes of the latter group were found to be sensitive to
(5Z)-7-Oxozeaenol inhibition.
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Table 3.1. Cluster analysis of mRNAs sensitive to TAK1 inhibition with over 1.7 fold
induction in response to TGFβ-1 treatment.

(N=2; DAVID Functional Annotation

Software). Cell cycle/Proliferation cluster
Affymetrix GENBANK Gene name
ID
ACCESSION

Fold
Increase

8116921

AK291838

endothelin 1

EDN1

6.7818

8024485

AF078077

growth arrest and DNA-damage-inducible, beta

GADD45B

2.39958

8139207

AK290584

inhibin, beta A

INHBA

2.04306

8026047

BC004250

jun B proto-oncogene

JUNB

1.87672

7922976

AK292167

PTGS2

1.92186

8147012

BC022265

PKIA

2.41012

8040473

AF498971

ras homolog gene family, member B

8010061

AF200328

sphingosine kinase 1

prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and cyclooxygenase)
protein kinase (cAMP-dependent, catalytic)
inhibitor alpha

RHOB
1.88318

SPHK1

1.72518
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Table 3.2. Cluster analysis of mRNAs sensitive to TAK1 inhibition with over 1.7 fold
induction in response to TGFβ-1 treatment.

(N=2; DAVID Functional Annotation

Software).
(A) Wound Healing cluster
Affymetrix

GENBANK

ID

ACCESSION

7950933

AB041035

8160637

AK297541

8072678

BC001491

8114572

Gene name

Fold
Increase

NADPH oxidase 4

NOX4

8.49418

B4GALT1

2.12002

heme oxygenase (decycling) 1

HMOX1

2.05866

BC033097

heparin-binding EGF-like growth factor

HBEGF

4.0607

8056184

AK290300

integrin, beta 6

ITGB6

2.41065

8039484

AK290572

interleukin 11

IL11

1.84543

8137670

AK292217

platelet-derived growth factor alpha polypeptide

PDGFA

2.07886

SERPINE1

2.17387

UDP-Gal:betaGlcNAc beta 1,4galactosyltransferase, polypeptide 1

serpin peptidase inhibitor, clade E (nexin,
8135069

AK293248

plasminogen activator inhibitor type 1), member 1
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(B) Cell motion, migration and adhesion cluster
Affymetrix

GENBANK

ID

ACCESSION

8023220

AF010193

8160637

AK297541

8116921

AK291838

8072678

Gene name

Fold
Increase

SMAD family member 7

SMAD7

2.841

B4GALT1

2.12002

endothelin 1

EDN1

6.7818

BC001491

heme oxygenase (decycling) 1

HMOX1

2.05866

8114572

BC033097

heparin-binding EGF-like growth factor

HBEGF

4.0607

8139488

AK298143

insulin-like growth factor binding protein 3

IGFBP3

1.88748

8137670

AK292217

platelet-derived growth factor alpha polypeptide

PDGFA

2.07886

8010061

AF200328

sphingosine kinase 1

SPHK1

1.72518

8148304

AF205437

tribbles homolog 1 (Drosophila)

TRIB1

2.96456

7962579

AY454159

adhesion molecule with Ig-like domain 2

AMIGO2

3.45511

8022674

BC036470

cadherin 2, type 1, N-cadherin (neuronal)

CDH2

2.04821

8035517

AK074508

cartilage oligomeric matrix protein

COMP

3.02008

8121685

AJ420528

discoidin, CUB and LCCL domain containing 1

DCBLD1

1.85226

8056184

AK290300

integrin, beta 6

ITGB6

2.41065

8102232

AF198532

lymphoid enhancer-binding factor 1

LEF1

1.90975

8123936

AK292682

NEDD9

2.93624

8047738

AL833606

neuropilin 2

NRP2

1.73487

8040473

AF498971

ras homolog gene family, member B

RHOB

1.88318

UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase,
polypeptide 1

neural precursor cell expressed, developmentally
down-regulated
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absence of (5Z)-7-Oxozeaenol and with and without TGFβ1 treatment. Six hours later
RNAs were extracted and subjected to RT-qPCR analysis. Confirming the gene array
data, both EDN1 and JUNB mRNA were found to be significantly induced by TGFβ1
ligand and application of the TAK1 selective inhibitor (5Z)-7-Oxozeaenol inhibited this
response (Figure 3.5). Indeed, in the presence of TGFβ1 and (5Z)-7-Oxozeaenol, EDN1
and JUNB mRNA expression were reduced to basal levels seen in DMSO treated
fibroblasts. Addition of (5Z)-7-Oxozeaenol did not have a significant effect on EDN1 and
JUNB mRNA expression (Figure 3.5).

3.4 TAK1 inhibition blocks TGFβ1-induced proliferation in gingival
fibroblasts.
To further elucidate gingival fibroblast proliferation at the functional level, I
cultured gingival fibroblasts under the four treatment conditions described previously in
the presence of BrdU, a synthetic thymidine analogue which is incorporated into the
newly-synthesized DNA (Figure 3.6). Presence of incorporated BrdU was assessed
quantitatively by absorbance readings at zero, 24, 48 and 72 hours. Addition of TGFβ1
significantly increased human gingival fibroblast proliferation at 48 and 72 hours as
compared to DMSO treated cells. Addition of (5Z)-7-Oxozeaenol resulted in a significant
reduction in cell proliferation responses measured at 72 hours to the levels below the
DMSO control group in the presence of added TGFβ1 (Figure 3.6). Consistent with the
gene cluster analysis, TAK1 inhibition blocked the ability of TGFβ1 to induce
proliferation in human gingival fibroblasts.
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Figure 3.5. Inhibition of TAK1 reduces TGFβ1-induced Endothelin 1 and Jun B
mRNA expression. Human gingival fibroblasts were serum starved overnight and pretreated with (5Z)-7-oxozeaenol (400 nM) or DMSO for 45 min followed by treatment
with TGFβ1 (4 ng/ml) ligand or left untreated. Total RNA was harvested six hours later
and subjected to TaqMan RT-qPCR analysis using the indicated probe/primer sets. 18S
RNA was used as the internal control. Note: the relative gene expression between DMSO
and (5Z)-7-oxozeaenol in the absence of TGFβ1 was not statistically significant. (N=3;
averages+/-SEM are shown. * p<0.05; Two-Way ANOVA followed by Tukey's Post Hoc
analysis).
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Figure 3.6. TAK1 mediates TGFβ1 induced gingival fibroblast proliferation. Human
gingival fibroblasts were serum starved overnight and pre-treated with (5Z)-7-oxozeaenol
((5Z)-7-oxo; 400 nM) or DMSO for 45 min followed by treatment with TGFβ1 (4 ng/ml)
ligand or left untreated. Cultures were grown in the presence of BrdU for up to 72 hours
as described in the methods. One of three representative experiments is shown; (N=4;
averages+/-SEM are shown * p<0.05 for: DMSO vs TGFβ1; (5Z)-7-oxo vs TGFβ1,
TGFβ1 vs (5Z)-7-oxo+TGFβ1; ** p<0.05 for: DMSO vs TGFβ1; (5Z)-7-oxo vs TGFβ1,
TGFβ1 vs (5Z)-7-oxo+TGFβ1. Two-Way ANOVA followed by Tukey's Post Hoc
analysis.
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3.5 TAK1 mediates TGFβ1- induced expression of wound healing cluster
mRNAs in gingival fibroblasts
Based on the expression profiling data, a wound healing cluster of eight genes as
well as a migration cluster consisting of eighteen genes were also identified (Table 3.2). I
decided to use RT-qPCR analysis to validate these observations and to further investigate
the role of TAK1 inhibition in the fibrotic component of the TGFβ1-dependent
fibroproliferative responses of fibroblast cells. Based on their known involvement with
fibrogenic responses, insulin-like growth factor binding protein 3 (IGFBP3) was chosen
from the migration/adhesion cluster group and platelet-derived growth factor-αpolypeptide (PDGFA), Interleukin-11 and SERPINE-1 genes were chosen from the
wound healing cluster group for the subsequent RT-qPCR analysis (Figure 3.7). IL11
was previously implicated as an anti-apoptotic mediator in lung fibroblasts derived from
Idiopathic Pulmonary Fibrosis patients and increased murine pulmonary myofibroblast
counts upon IL11 overexpression were also reported (Moodley et al., 2003). PDGFA is a
secreted protein and mitogen belonging to the Platelet-derived growth factor family
found to be overexpressed in a number of fibrotic conditions including pulmonary
fibrosis and scleroderma at the level of fibroblasts/myofibroblasts (Trojanowska 2008).
IGFBP3 is another secreted protein associated with increased ECM production and ECM
binding in a TGFβ-dependent manner. Increased expression of IGFBP3 was observed in
dermal fibroblasts from scleroderma patients and lung fibroblasts from idiopathic
pulmonary fibrosis patients (Pilewski et al., 2005). Finally, elevated levels of SERPINE1,
a pro-fibrogenic factor, were observed in the dermal fibroblasts isolated from the lesions
of scleroderma patients (Dong et al., 2002; Ghosh
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Figure 3.7. Inhibition of TAK1 reduces the expression of TGFβ1 induced wound
healing genes. Human gingival fibroblasts were serum starved overnight and pre-treated
with (5Z)-7-oxozeaenol (400 nM) or DMSO for 45 min followed by treatment with
TGFβ1 (4 ng/ml) ligand or left untreated. Total RNA was harvested six hours later and
subjected to TaqMan RT-qPCR analysis using the indicated probe/primer sets. 18S RNA
was used as the internal control. Note: the relative gene expression between DMSO and
(5Z)-7-oxozeaenol in the absence of TGFβ1 was not statistically significant. (N=3;
averages+/-SEM are shown. * p <0.05, Two-Way ANOVA followed by Tukey's Post
Hoc analysis).
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and Vaughan, 2012). RT-qPCR analysis confirmed the gene array data, showing that
IL11, PDGFA, IGFBP3 and SERPINE1 mRNAs were significantly induced by TGFβ1 in
a fashion that was sensitive to TAK1 inhibition (Figure 3.7). Baseline expression of all
of the chosen genes was not significantly affected with the addition of (5Z)-7Oxozeaenol.
Collectively, these data suggest that TAK1 mediates TGFβ1 responses in gingival
fibroblasts including proliferation, wound healing as well as CCN2 expression.
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4. Discussion
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4.1 Summary of results
Although previous studies have shown that the non-canonical, TAK1-mediated
signaling pathway plays a role in dermal fibroblasts and in physiological wound healing
in the skin, the involvement of non-canonical TAK1 signaling in TGFβ1 driven, profibrotic or hyper-proliferative responses in gingival fibroblasts has not been previously
examined (Guo et al., 2012). I thus thought that, as in dermal fibroblasts, TAK1 may
mediate wound healing and proliferative responses in gingival fibroblasts in response to
TGFβ1. Throughout my studies I have used a TAK1 selective inhibitor

(5Z)-7-

Oxozeanol to test this hypothesis in the context of TGFβ1 signaling in gingival
fibroblasts using concentrations and treatment conditions previously established for
fibroblasts in culture (Guo et al., 2012; Renzoni et al., 2004 ). As an initial screen, I asked
if (5Z)-7-Oxozeanol could block TGFβ1- induced CCN2 expression, given that CCN2 is
a known marker and mediator of fibrosis (Brigstock 2010; Chen and Lau, 2009; Leask,
2008, 2009; 2011; 2013a, 2013b, Thompson et al., 2010). Indeed, (5Z)-7-Oxozeanol
significantly reduced TGFβ1-induced CCN2 expression at both transcriptional and
translational levels as evidenced by the RT-qPCR and indirect immunofluorescence
microscopy/Western blot respectively (Figures 3.1, 3.2 and 3.3). Genome wide
expression profiling allowed me to further identify functional clusters of genes grouped
based on their involvement in a given functional outcome. I have identified a number of
TGFβ1-induced genes sensitive to TAK1 inhibition from the proliferative and wound
healing (including migratory) clusters (Tables 3.1 and 3.2, respectively). Moreover, the
majority of the genes induced with TGFβ1 were in fact sensitive to TAK1 inhibition,
suggesting that the non-canonical TAK1 pathway is of critical importance in the gingival
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fibroblasts in response to TGFβ1. I have also confirmed this pattern of regulation for a
number of representative genes from each functional cluster at the transcriptional level
using RT-qPCR (Figures 3.5 and 3.7). Of interest also was the observation that unlike
skin wounds, gingival wounds heal faster and without scarring, possibly due to the fact
that unlike fibroblasts from the dermis layer of the skin, gingival fibroblasts are also less
able to differentiate into α-SMA-expressing myofibroblasts in vitro and in vivo: gingival
hyperplasia overgrowths are not populated by myofibroblast and with respect to fibrotic
conditions, such as gingival hyperplasia, a hyperproliferative phenotype is observed
(Egusa et al., 2010; Guo et al., 2011a, 2011b; Schor et al., 1996, Wikesjo et al., 1992). I
thus became interested whether the TGFβ1-induced proliferation in gingival fibroblasts
may be mediated by TAK1 and whether TAK1 inhibition using an exogenously
administered inhibitor could in theory be applied to alleviate the fibro-proliferative
responses in gingival hyperplasia in the future. Indeed, increased proliferative responses
of gingival fibroblasts upon TGFβ1 treatment were reduced to baseline levels with the
application of TAK1 selective inhibitor (5Z)-7-Oxozeanol (Figure 3.6). Collectively, my
work suggests that TAK1 mediates proliferation and wound healing responses to TGFβ1
in gingival fibroblasts. The results are also consistent with my long-term hypothesis that
TAK1 inhibition might be used to treat gingival hyperplasia and that further investigation
of TAK1-mediated TGFβ1 signaling in gingival fibroblast cells may lead to a better
understanding of a) the basis of gingival scarless repair and b) the role of the noncanonical, TAK1- mediated TGFβ1 signaling as it pertains to the hyper-proliferative
response associated with this fibroblast cell type.
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4.2 Research significance
My results are consistent with the overall hypothesis that TAK1 inhibitors such as
(5Z)-7-Oxozeanol may be considered in the future for gingival hyperplasia treatment.
Unlike other areas of the body which scar in response to injury, gingival wounds heal
faster and without scarring, although the stages of the healing process and their sequence
remain similar between the two tissue types (Egusa et al., 2010; Guo et al., 2011a, 2011b;
Schor et al., 1996, Wikesjo et al., 1992). One of the possible explanations for this
differential phenotype is that fibrotic responses in the gingiva are hyper-proliferative as
opposed to hypercontractile (Bitu et al., 2006; Damasceno et al., 2012; Sobral et al.,
2010). The basis of this differential phenotype could be that gingival fibroblasts differ
from dermal fibroblasts in their response to endogenous and/or exogenous stimuli,
resulting in gingival overgrowth and hyperplasia (Guo et al., 2011a, 2011b). Gingival
hyperplasia commonly arises as a side-effect to a number of drugs including antiepileptic
medications, immunosuppressant drugs and as well as calcium channel blockers
(Clocheret et al., 2003; Nakib and Ashrafi, 2011). Prevalence of gingival hyperplasia
associated with Diltiazem (calcium channel blocker) reaches 20% while Cyclosporine
(immunosuppressant) or Phenytoin (antiepileptic treatment) are associated with 30% and
40-50% prevalence rate respectively (Boltchi et al., 1999; Casetta et al., 1997; Ciancio et
al., 1991; Dahlof et al., 1993; Fu et al., 1998; Myers and Newton, 1991; Steinberg 1981).
As of 1995, over 20 prescription medications were associated with gingival enlargement
in the United States (Rees et al., 1995). Withdrawal from drug therapy or substitution for
a different drug serves as the most effective treatment for gingival hyperplasia however
gingivectomy

(surgical

debridement)

may

be

necessary

in

cases

where
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withdrawal/substitution are not possible or in all other cases of gingival hyperplasia
(including

inflammation,

idiopathic

gingival

hyperplasia,

gingivitis,

genetic

predisposition) (Khocht et al., 1997; Marshall et al., 1999; Somacarrera et al., 1997).
TGFβ1, a member of TGFβ superfamily, promotes wound healing and fibrotic
responses both in vitro and in vivo (Leask 2008). Fibroblasts are the cells present in the
connective tissue that mediate tissue repair and fibrosis. Fibroblast activation in response
to TGFβ1 involves both canonical Smad-dependent and non-canonical Smad-independent
pathways (Leask 2006, 2008; Leask and Abraham, 2004; Massague 1998; Rahimi and
Leof, 2007). At the level of transcriptome, close to 95% of genes were up-regulated in
response to TGFβ1 in gingival fibroblasts were found to be sensitive to TAK1 inhibition.
In contrast, only 67% of genes were not induced by TGFβ1 in the presence of (5Z)-7Oxozeaenol in dermal fibroblasts in a study using comparable fold cut-off value (1.7
fold) and treatment conditions (400 nM (5Z)-7-Oxozeaenol; 4 ng/ml TGFβ1) (Guo et at.,
2012). Thus, compared to dermal fibroblasts, the vast majority of TGFβ1 signaling
responses in gingival fibroblasts are mediated via the non-canonical TAK1 pathways. In
dermal fibroblasts, wound healing and ECM gene clusters were identified for the TGFβ1
induced genes sensitive to TAK1 inhibition (Guo et at., 2012). Similarly, the wound
healing cluster under TAK1 regulation was also identified in gingival fibroblasts in the
current study, as well as a cluster cell proliferation.
CCN2, a member of the CCN family of matricellular proteins is both a marker
and a mediator of fibrosis (Blom et al., 2002; Brigstock 2010; Chen and Lau, 2009;
Leask, 2008, 2009; 2011; 2013a, 2013b, Thompson et al., 2010). CCN2 expression is
also known to be induced by TGFβ1 in gingival and dermal fibroblasts and expression of
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this protein correlates well with tissue fibrosis and fibrotic cells (Brigstock, 2010; Chen
and Lau, 2009; Guo et al., 2011a, 2011b; Leask, 2008, 2011). In gingival and dermal
fibroblasts, TGFβ1-induced CCN2 expression is known to involve canonical signaling
pathways (Guo et al., 2011a; Holmes et al., 2001; Thompson et al., 2010). Previously,
mRNA and protein expression of CCN2 in dermal fibroblasts were found to be reduced
with the (5Z)-7-Oxozeanol, a selective inhibitor of the non-canonical TAK1 signaling in
response to TGFβ1 treatment. Here I show for the first time that (5Z)-7-Oxozeanol
suppresses the ability of TGFβ1 to induce CCN2 mRNA as well as protein expression in
gingival fibroblasts. CCN2 expression in response to TGFβ1 may thus be subject (at least
in part) to the non-canonical regulation in both dermal and gingival fibroblasts.
Previous studies demonstrated that CCN2 showed increased expression in fibrotic
tissues where it promoted fibrosis by activating adhesive signaling (Brigstock, 2010;
Chen and Lau, 2009; Leask, 2008, 2011). Adhesive properties of gingival and dermal
fibroblasts were also previously assessed using dermal or gingival fibroblast monolayers
cultured on collagen type I and III, fibronectin and vitronectin substrates. Dermal
fibroblasts were more spread out and displayed increased number of focal adhesions and
actin stress fibers as compared to gingival fibroblasts up to 24 hours post adhesion on
either collagen type I or fibronectin substrates (Guo et al., 2011a; 2011b). Adhesion via
FAK is essential for TGFβ1-induced human fetal lung myofibroblast differentiation
(Thannickal et al., 2003). FAK is further involved in driving myofibroblast differentiation
via the non-canonical TGFβ signaling pathway involving FAK-mediated JNK activation
via MEKK1 (Shi-wen et al., 2009). FAK forms a complex with integrin receptors is and
activated upon integrin mediated fibroblast attachment to the substrate (Lagares et al.,
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2012; Michael et al., 2009; Shi-wen at al., 2012). Addition of FAK inhibitor or deletion
of FAK in fibroblasts decreased the expression of fibrogenic genes and blocked fibrosis
in vivo (Lagares et al., 2012; Shi-wen et al., 2012). Inhibitors of FAK and integrins (β1)
have been proposed as potential therapeutic agents in alleviating the symptoms of
scleroderma disease (Shi-wen et al., 2012). Interestingly, the endogenous levels of FAK
protein are also reduced in gingival fibroblasts as compared to dermal fibroblasts (Guo et
al., 2011a, 2011b) perhaps accounting (at least in part) for the impaired myofibroblast
differentiation potential and impaired adhesion kinetics of gingival fibroblasts as
compared to dermal fibroblasts. Induction of TAK1 upon TGFβ stimulation was further
reduced upon pre-treatment of wild type mouse embryonic fibroblasts with the FAK/Src
inhibitor PP2, or with the use of FAK -/- fibroblasts, suggestive of FAK-dependent
induction of TAK1 in TGFβ signaling (Shi-wen et al., 2009). As TAK1-dependent
TGFβ1 signaling operates in both gingival and dermal fibroblasts, additional signaling
pathways must be responsible for the fibro-contractile phenotype observed in fibrotic
tissue in other parts of the body. Indeed, Chen and others report TGFβ1-induced
contraction of dermal fibroblasts to be syndecan 4 and MEK/ERK dependent; notably,
ERK was required for assembly of α-SMA stress fibers and hence ECM contraction
(Chen et al., 2005). Alternatively, TGFβ1 signaling may be subject to epigenetic
regulation in gingival versus dermal fibroblasts, accounting for scarless repair; indeed,
recent results from our laboratory suggest that expression of microRNA MIR218 is
altered between gingival and dermal fibroblasts (Guo et al., 2014).
Endothelin-1 was also chosen as a representative gene from the proliferative
cluster showing decreased TGFβ1-mediated mRNA expression levels with (5Z)-7-
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Oxozeaenol pre-treatment. ET-1 belongs to a family of peptides originally recognized for
their role as vasoconstrictors and section from vascular endothelial cells (Horstmeyer et
al., 2005; Kawaguchi et al., 1994; Shi-wen et al., 2006). Levels of ET-1 expression were
found to be increased in a number of fibrotic disease conditions including drug induced
gingival overgrowth and gingival fibrosis (Abraham et al., 1997; Kawaguchi et al., 1994;
Leask, 2008; Miyauchi et al., 1992; Morelli et al, 1995; Shi-Wen et al., 2006; Subramani
et al., 2013; Tamilselvan et al., 2007; Vancheeswaran et al., 1994; Yamane et al, 1992).
ET-1 is a 21-amino acid ligand produced by fibroblasts and other cell types (epithelial
and endothelial cells, cardiomyocytes, smooth muscle and immune cells) in a form of an
inactive prepro-ET1 which is further processed by endopeptidase and endothelinconverting enzyme (ECE) into a proET-1 and active ET-1 respectively (Horstmeyer et
al., 2005; Kawaguchi et al., 1994; Leask 2008; Shi-wen et al., 2001, 2006; Tamilselvan et
al., 2007). ET-1 acts synergistically with TGFβ to promote differentiation of fibroblasts
into myofibroblast and is also induced by, and mediates downstream signaling in
response to TGFβ (Galie et al., 2004; Horstmeyer et al., 2005; Krieg et al., 2007; Rahimi
and Leof, 2007; Rodriguez et al., 2003; Shephard et al., 2004). Stimulation of dermal
fibroblasts with ET-1 alone did not lead to sufficient up-regulation of α-SMA, a marker
of myofibroblast differentiation while a synergistic increase in α-SMA expression was
observed upon co-stimulation with ET-1 and TGFβ1(Shephard et al., 2004). Similarly,
inhibition of endogenous TGFβ1 activity using a neutralizing antibody as well as coinhibition of ET-1 activity were required to completely prevent α-SMA expression in
keratinocyte-fibroblast co-cultures (Shephard et al., 2004). Interestingly, gingival
fibroblasts possess reduced EDN1 mRNA and ET-1 protein expression as compared to
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human dermal fibroblasts. Subjecting gingival fibroblasts to mechanical strain or a six
hour induction with TGFβ1 (4ng/ml) did not result in up-regulation of collagen type I or
αSMA, as was the case with dermal fibroblasts under the same culture conditions (Guo et
al., 2011a,b). These differences in the αSMA and collagen I induction between the two
cell types were rescued upon co-incubation of gingival fibroblasts with both TGFβ and
ET-1. That myofibroblast differentiation is relatively absent in fibrotic conditions such as
gingival hyperplasia may thus be partially explained by the reduced gingival fibroblast
responsiveness (αSMA and collagen expression) to mechanical strain and TGFβ1
induction as a result of a reduced production of ET-1, as compared to dermal fibroblast
cells (Bitu et al., 2006; Damasceno et al., 2012; Guo et al., 2011a,b; Sobral et al., 2010).
Aside from the active role in ECM remodeling and myofibroblast differentiation,
ET-1 exhibits mitogenic properties as well as production of PDGF and TNF-α
inflammatory cytokines and TGFβ1 (Chamnez et al., 1996; Gandhi et al., 2000;
Horstmeyer et al., 2005; Nakamura et al., 1995; Shi-wen et al., 2001). Expression of ET1 upon TGFβ1 treatment was found to be subject to canonical as well as non-canonical
JNK regulation in human dermal and mouse embryonic fibroblasts (Lagares et al., 2010).
Furthermore, ET-1 expression in response to TGFβ1 is Smad-independent in the
pulmonary fibroblast cells subject to comparable TGFβ1 induction (4 ng/ml) and is
instead mediated via the JNK/c-Jun/activator protein-1(AP-1) (Krieg at al., 2007; ShiWen et al., 2006). As these data suggest that TAK1 regulates JNK activation, the noncanonical TAK1 signaling pathways may mediate TGFβ1 induced ET-1 expression in
lung fibroblasts (Rahimi and Leof, 2007). Based on the results I present here, TGFβ1induced EDN1 mRNA expression was blocked by TAK1 selective inhibitor, suggesting
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that ET-1 may be regulated in a similar fashion in both pulmonary and gingival
fibroblasts. Inhibition of TAK1 in gingival fibroblasts may lead to inhibition of the
JNK/c-Jun/activator protein-1(AP-1) signaling similar to what was reported in pulmonary
fibroblasts (Rahimi and Leof, 2007). In fibroblasts, TGFβ1 and ET-1 synergize to
promote myofibroblast differentiation (Shephard et al., 2004). It also is interesting to note
that basal ET-1 expression in human gingival fibroblasts is lower than that in dermal
fibroblasts and this lower level of expression may explain why TGFβ1 is relatively
unable to induce myofibroblast differentiation in gingival fibroblasts (Guo et al., 2011a,
2001b)

4.3 Limitations and future research
The results suggest that TAK1 pathway operates in gingival fibroblasts and
mediates essentially all responses to TGFβ1, including proliferation and CCN2 induction.
These results must nevertheless be interpreted with caution since the mRNA expression
levels of individual genes should not be examined in the context of gene expression
profiling alone, but needs independent verification through other procedures. In this
thesis, the results obtained using gene array profiling were verified using real time PCR
analysis and functional assay.
A confounding factor may be equally present among the various treatment
conditions in this study, as I cultured gingival fibroblasts on rigid, stiff plastic tissue
culture plates. Progressive increases in the matrix stiffness during normal wound healing
is thought to correlate with fibroblast-myofibroblast differentiation as mechanical tension
encourages the formation of focal adhesion and stress fibers (Hinz, 2010; Hinz et al.,
2001; Balestrini et al., 2012). In theory, this finding is not surprising given the current
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knowledge of the role of ECM in sheltering the residing fibroblasts from the outside
mechanical forces as well as the observation of a loss of fibroblast phenotype and
emergence of myofibroblasts when the “stress-shielding” capacity of ECM is lost upon
injury (Guo et al., 2011a, 2011b; Hinz and Gabbiani 2003). In addition, the later stages
of wound healing response are characterized by the ECM remodeling and increases in the
ECM stiffness. Compliant, two-dimensional matrices were therefore developed in the
past with polyacrylamide, polyvinyl alcohol or silicone based elastomers (Hinz, 2010).
Although soft, two dimensional matrices are thought to serve as better models of
true tissue compliance, the use of such compliant two dimensional matrices is also not
without limitations. First, the true tissue compliance is complex and not homogenous
(Hinz, 2010). Second, matrices of polyacrylamide or silicone cannot be remodeled by the
attached fibroblast cells as these synthetic substances are not biologically degradable
(Hinz, 2010). This creates several important limitations in terms of experimental design.
Increases in the deposition of collagen and other factors by the cultured cells may
overcome the effects of the underlying soft matrix, effectively increasing its stiffness
(Hinz 2010). The degree of culture confluence may further overturn the effect of soft
matrix when the increased formation of cell-cell contacts leads to increased mechanical
tension exerted on the cell culture by cells (Hinz 2010).

In contrast, the three-

dimensional matrices of collagen or fibronectin completely surround cells in culture and
may better represent the microenvironment encountered by the fibroblast in the lamina
propria layer (Grinnell, 2003). Three dimensional culture matrices have been also
previously employed to better recreate the physiological conditions experienced by the
fibroblasts in the dermis or lamina propria layers, including the presence of cell-cell and
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cell-matrix adhesions, regulation of cellular proliferation and growth as well as in vivo
wound healing and remodeling responses (Chaussain Miller et al., 2002).
Consequently, although it might have been interesting to compare the responses
of gingival fibroblast cultured on more compliant and elastic substrates or in using three
dimensional matrices, that TGFβ1 still potently induced gene expression and proliferation
of cells cultured on plastic suggests that alteration in fibroblast phenotype due to
culturing cells on plastic is not sufficient to cause a complete differentiation of fibroblasts
to myofibroblast. CCN2 is both a marker and a mediator of fibrosis, and expression of
this protein correlates well with tissue fibrosis and fibrotic cells (Brigstock, 2010; Chen
and Lau, 2009; (Guo et al., 2011a, 2011b; Leask, 2008, 2011). I did not detect basal
CCN2 protein expression (DMSO treatment group) using two separate methods of
analysis: western blot and immunofluorescence microscopy and should gingival
fibroblast cells undergo this process of differentiation in response to the stiff, plastic
substrate, high basal expression of CCN2 in cultured gingival fibroblasts would have
been apparent. Further, induction of gingival fibroblast monolayers with TGFβ1 lead to
robust responses not only in CCN2 expression (mRNA and protein) but also in the
expression of wound healing and proliferative genes as well as measures of gingival
fibroblast proliferation using a functional assay. Had gingival fibroblast cells undergone
the process of differentiation in response to the stiff substrate, additional induction with
TGFβ1 would likely have not caused significant effects. That fibrotic conditions such as
gingival hyperplasia are characterized by increased proliferation of fibroblast cells, as
opposed to differentiation into myofibroblasts, further supports the notion that gingival
fibroblasts respond differently to the fibrogenic stimuli such as TGFβ1 induction or
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“stress-unshielded” environment provided by the rigid plastic culture vessel (Bitu et al.,
2006; Damasceno et al., 2012; Sobral et al., 2010). Three-dimensional collagen or
fibronectin lattices

nevertheless

may be utilized in the future studies of gingival

fibroblast ECM remodeling in the presence and absence of (5Z)-7-oxozeaenol.
The use of an animal model to study the role of TAK1 in gingival fibroblasts
should be considered for the future. Full body MAP3K7-KO (deletion of TAK1) mice die
in utero during early embryogenesis (E10) likely due to impaired neural tube
development (Shim et al., 2005). Thus, in order to study TAK1 in vivo, a number of mice
strains were generated allowing for conditional MAP3K7 (TAK1) deletion from various
cell types such as: mouse embryonic fibroblast (MEF) cells, myocardium, hepatocytes,
intestinal epithelial cells, keratinocytes, cartilage and fibroblast cells (Inokuchi et al.,
2010; Kajino-Sakamoto et al. 2008; Liu et al., 2006; Ma et al., 2011; Omori et al., 2006;
Sato et al., 2005; Shim et al. 2009; Xie et al., 2006; Zhang et al., 2000; Zheng et al.,
2002). In particular, a fibroblast-specific MAP3K7-KO mouse model may be considered
for subsequent studies of TAK1-mediated signaling in gingival fibroblasts, wound
healing functional assessment as well as nifedipine-induced gingival hyperplasia in mice
as was previously reported using rat models (Kataoka et al., 2001). In the former,
fibroblast explants from gingiva of control (C57/BL6) as well as fibroblast specific
TAK1-KO mice may be studied in greater detail in response to TGFβ1 induction or
mechanical strain in culture, with subsequent analysis of the canonical and non-canonical
signaling pathways. A similar study has been conducted using an established fibroblast
specific MAP3K7-KO mouse model where the loss of TAK1 resulted in impaired
proliferative, adhesive and migratory properties of cultured dermal fibroblasts (Guo et al.,
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2012). Further, the phenotypic differences in gingival tissues of the control and fibroblast
specific MAP3K7-KO mice may be monitored histologically in response to oral
administration of nifedipine (Nalini et al., 1990) or in response to the administration of
other drugs which are known to be associated with gingival hyperplasia induction.
Compared to studies relying on the genetic knock-out of MAP3K7, studies using a
small molecule may be better suited for the translational, bench-to-bedside research
approach. (5Z)-7-Oxozeaenol has been previously administered to mice and rats. A two
week IP injection of (5Z)-7-Oxozeaenol into female nude mice at 15 mg/kg resulted in
neuroblastoma

sensitization

to

doxorubicin

(Dox)

and

etoposide

(VP-16)

chemotherapeutic drugs using orthotopic neuroblastoma mouse model (Fan et al., 2013).
Intracerebroventricular as well as IP injection of (5Z)-7-Oxozeaenol into male mice at
various doses accounted for a promising neuroprotective therapeutic approach in stroke
treatment (White et al, 2012).

Further, adult male Sprague–Dawley rats injected

intracerebroventricularly with (5Z)-7-oxozeaenol exhibited improved neurological
function and neuronal survival after induced traumatic brain injury (Zhang et al., 2013).
Unfortunately, studies primarily focusing on the safety of systemic (5Z)-7-oxozeaenol
administration as well as pharmacokinetic and pharmacodynamic properties still remain
to be conducted in the future, including pre-clinical trials and Phase I clinical trials in
humans. Should local application of (5Z)-7-oxozeaenol be considered for gingival
hyperplasia treatment, the overall effect of this ligand on the oral mucosa and underlining
tissues as well as the effect on gastrointestinal tract must also be established.
A number of additional TAK1 inhibitors including Pyrazolo[4,3-c]isoquinolines
and 5Z-7-oxozeaenol analogues have been recently identified and may be considered for
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treatment of gingival hyperplasia and/or study of TAK1-mediated signaling responses
(Buglio et al., 2012, Lockman et al., 2011, and Mortier et al., 2010). Oral administration
of TAK1 inhibitors may also be considered in the future where a study using orally
administered LYTAK1, a small molecule inhibitor of TAK1, showed a reduction of
TAK1-mediated resistance to chemotherapeutic drugs for pancreatic adenocarcinoma
treatment in orthotopic nude mouse model (Melisi et al., 2011).
Collectively, my results suggest that TAK1 mediates the ability of TGFβ1 to
induce CCN2 expression (mRNA and protein) and transcriptional responses in gingival
fibroblasts. Notably, TAK1 inhibition blocks the ability of TGFβ1 to elicit proliferative
responses as well as the expression of wound healing genes in gingival fibroblasts. My
thesis described data supporting the long-term hypothesis that targeting the non-canonical
TAK1-mediated TGFβ1 signaling pathway may be useful to combat gingival hyperplasia
in the future.
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Supplemental Table 3.3. List of genes sensitive to TAK1 inhibition with over 1.7 fold
induction in response to TGFβ-1 treatment (N=2).
Affymetrix
ID
7918857
8067233
7950933
8116921
8109159
8156919
8112045
8131600
7970793
8114572
7922162
7972750
8175261
7962579
7933075
8095043
7954511
8008885
8035517
8088550
8148304
8123936
7922328
8023220
8077490
7966026
7987315
7958352
7962689
8160439
8113504
8115490
7900510
8161701
8023995
8056184
8147012
8024485
7990873
7974335

Genbank
Accession
GU971730
AJ308020
AB041035
AK291838
ENST00000384967
AK300099
AK300634
BC033863
AK093932
BC033097
AB209540
BC151220
ENST00000385270
AY454159
AF086500
AY839725
AB023182
ENST00000362134
AK074508
AK127113
AF205437
AK292682
ENST00000385289
AF010193
AF216709
BC152462
BC009978
AK091276
AF026260
ENST00000362307
ENST00000446294
AF134707
AK130549
AF137030
AK291958
AK290300
BC022265
AF078077
AB095929
ENST00000515947

Gene Name
TSPAN2
PMEPA1
NOX4
EDN1
MIR145
MURC
ESM1
TSPAN13
SLC46A3
HBEGF
SLC19A2
COL4A1
MIR503
AMIGO2
FZD8
RASL11B
STK38L
MIR21
COMP
PRICKLE2
TRIB1
NEDD9
MIR199A2
SMAD7
LMCD1
NUAK1
ACTC1
BTBD11
VDR
MIR31
NREP
ADAM19
CTPS1
TMEM2
FSTL3
ITGB6
PKIA
GADD45B
MEX3B
RN5S385

Fold
Increase
12.5003
9.40699
8.49418
6.7818
4.99812
4.93433
4.31011
4.15714
4.09995
4.0607
4.05461
3.80166
3.63312
3.45511
3.37736
3.35287
3.3435
3.25119
3.02008
3.00856
2.96456
2.93624
2.91144
2.841
2.81825
2.68415
2.64134
2.63841
2.55848
2.53933
2.53329
2.44597
2.44545
2.43863
2.43461
2.41065
2.41012
2.39958
2.38217
2.38034
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Affymetrix
ID
8159900
8160435
8143154
8109157
7958202
8169240
8136341
8151334
8121257
7950391
7926545
7933872
7934434
8135069
7993588
8112803
7970033
8057990
7997642
7959361
8160637
7972557
8023415
7923173
8137670
8041206
8072678
8109426
8022674
8139207
8114970
7950374
7905428
8116418
7906995
8111430
8123104
8156571
7936322
7979710
7922773
8162940
7965094

Genbank
Accession
BC033899
AY358570
AK091081
NR_029684
AB042326
AK297968
BC017050
BC006313
AF084199
AB019210
AF378757
AF139463
AF240633
AK293248
AK094664
BC136335
ENST00000400163
AK301209
AK027395
BC151841
AK297541
BC020752
AK299169
ENST00000385240
AK292217
AF110224
BC001491
ENST00000524264
BC036470
AK290584
AY358656
AK300598
AK299925
AB016789
BT006860
EF560721
BC146783
ENST00000385129
AL833061
AF228603
AF527950
AB055982
BC017481

Gene Name
GLIS3
IFNE
DGKI
MIR143
CHST11
PRPS1
BPGM
MSC
PRDM1
PGM2L1
PLXDC2
EGR2
MYOZ1
SERPINE1
TMC7
LHFPL2
COL4A2
ANKRD44
CRISPLD2
MLXIP
B4GALT1
GPR183
TCF4
MIR181B1
PDGFA
LBH
HMOX1
FLJ38109
CDH2
INHBA
C5orf46
P4HA3
TUFT1
GFPT2
UCK2
AMACR
FNDC1
MIR27B
GPAM
PLEK2
NCF2
ABCA1
E2F7

Fold
Increase
2.37678
2.3663
2.34734
2.33962
2.28914
2.2807
2.27611
2.26058
2.25456
2.25386
2.23225
2.22617
2.2035
2.17387
2.17183
2.14818
2.14259
2.13067
2.12702
2.12286
2.12002
2.10273
2.10147
2.09207
2.07886
2.07127
2.05866
2.05775
2.04821
2.04306
2.04245
1.99257
1.98978
1.98967
1.98699
1.97704
1.9678
1.96393
1.95685
1.95078
1.94535
1.94403
1.93429
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Affymetrix
ID
7991080
7972239
7922976
8063634
8021707
8094751
8156573
8102232
7943803
8035896
7953981
7934997
8139488
7986789
8040473
7944302
8026047
7974316
8154962
7922889
7950555
8167013
8088776
8161945
8121685
8039484
8005661
8109407
8060850
8020455
7909494
8103695
8095767
8026198
7965112
7922326
8092836
8054997
8056257
7999909
7944722
8157253
8072705

Genbank
Accession
AK302992
BC101070
AK292167
BC002831
BC020082
BC113549
AF480560
AF198532
AK055899
AK293267
AK289441
AK299392
AK298143
BC038712
AF498971
AB094090
BC004250
BC020521
AF088982
ENST00000367498
BC070079
ENST00000424392
AF146696
ENST00000376447
AJ420528
AK290572
AK304186
AB078145
ENST00000378827
U66075
BC130323
AK290041
AK074237
ENST00000440752
ENST00000550006
ENST00000385214
BC031569
AK074577
U76833
AF181862
AF425252
ENST00000374232
AF279143

Gene Name
BNC1
SLITRK6
PTGS2
MGC4294
SOCS6
CHRNA9
MIR24-1
LEF1
DIXDC1
TSHZ3
ETV6
PPP1R3C
IGFBP3
ATP10A
RHOB
PHLDB1
JUNB
FRMD6
DNAJB5
IVNS1ABP
LRRC32
PHF16
FOXP1
RASEF
DCBLD1
IL11
SPECC1
GALNT10
BMP2
GATA6
SYT14
MFAP3L
C4orf26
ZSWIM4
PAWR
MIR3120
CPN2
MAP3K2
FAP
GPRC5B
UBASH3B
SNX30
RASD2

Fold
Increase
1.93384
1.93138
1.92186
1.91941
1.91887
1.91164
1.91017
1.90975
1.90939
1.9092
1.90186
1.89232
1.88748
1.88652
1.88318
1.87993
1.87672
1.8761
1.87319
1.87315
1.86387
1.86357
1.86169
1.85336
1.85226
1.84543
1.84376
1.82627
1.81767
1.81052
1.80486
1.79877
1.79371
1.79067
1.78964
1.78538
1.77686
1.77627
1.77509
1.76782
1.75863
1.75667
1.75216
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Affymetrix
ID
8157802
8142415
8058477
8047738
8010061
8025402
8151816
7956271
8104035
8155192
7943998
7901993
8141241

Genbank
Accession
ENST00000385004
AK299901
AK297312
AL833606
AF200328
AB056477
BC022010
AF016509
AK056628
AK091288
BC000234
AK299361
ENST00000361125

Gene Name
MIR181B2
C7orf60
KLF7
NRP2
SPHK1
ANGPTL4
GEM
HSD17B6
SORBS2
GLIPR2
NNMT
CACHD1
SMURF1

Fold
Increase
1.74598
1.74074
1.73553
1.73487
1.72518
1.72498
1.72429
1.7231
1.72124
1.71552
1.711
1.70334
1.70312
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Supplemental Table 3.4. List of genes with over 1.7 fold induction in response to
TGFβ-1 treatment (N=2).

Affymetrix
ID
7918857
8067233
7950933
8116921
7974689
8109159
8156919
8112045
8131600
7970793
8114572
7922162
7972750
8175261
7962579
7933075
8095043
7954511
8008885
8035517
8088550
8083876
8148304
8123936
7922328
8023220
8077490
7966026
7987315
7958352
8178435
8129562
7962689
8160439
8077441
8113504
8124848
8179704

Genbank
Accession
GU971730
AJ308020
AB041035
AK291838
AF251079
ENST00000384967
AK300099
AK300634
BC033863
AK093932
BC033097
AB209540
BC151220
ENST00000385270
AY454159
AF086500
AY839725
AB023182
ENST00000362134
AK074508
AK127113
AK300053
AF205437
AK292682
ENST00000385289
AF010193
AF216709
BC152462
BC009978
AK091276
AF083421
AK290884
AF026260
ENST00000362307
AB004066
ENST00000446294
BC005080
AF083421

Gene Name
TSPAN2
PMEPA1
NOX4
EDN1
DACT1
MIR145
MURC
ESM1
TSPAN13
SLC46A3
HBEGF
SLC19A2
COL4A1
MIR503
AMIGO2
FZD8
RASL11B
STK38L
MIR21
COMP
PRICKLE2
SKIL
TRIB1
NEDD9
MIR199A2
SMAD7
LMCD1
NUAK1
ACTC1
BTBD11
IER3
CTGF
VDR
MIR31
BHLHE40
NREP
IER3
IER3

Fold
Increase
12.5003
9.40699
8.49418
6.7818
5.38907
4.99812
4.93433
4.31011
4.15714
4.09995
4.0607
4.05461
3.80166
3.63312
3.45511
3.37736
3.35287
3.3435
3.25119
3.02008
3.00856
2.96522
2.96456
2.93624
2.91144
2.841
2.81825
2.68415
2.64134
2.63841
2.57544
2.55987
2.55848
2.53933
2.5374
2.53329
2.51526
2.51526
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Affymetrix
ID
8115490
7900510
8161701
8023995
8056184
8147012
8024485
7990873
7974335
8159900
8160435
8143154
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7926545
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8139207
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Gene Name
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FSTL3
ITGB6
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GADD45B
MEX3B
RN5S385
GLIS3
IFNE
DGKI
MIR143
CHST11
PRPS1
BPGM
MSC
PRDM1
PGM2L1
PLXDC2
EGR2
MYOZ1
KLF10
SERPINE1
TMC7
LHFPL2
COL4A2
ANKRD44
CRISPLD2
MLXIP
B4GALT1
GPR183
TCF4
MIR181B1
PDGFA
LBH
HMOX1
FLJ38109
CDH2
INHBA
C5orf46
P4HA3
TUFT1

Fold
Increase
2.44597
2.44545
2.43863
2.43461
2.41065
2.41012
2.39958
2.38217
2.38034
2.37678
2.3663
2.34734
2.33962
2.28914
2.2807
2.27611
2.26058
2.25456
2.25386
2.23225
2.22617
2.2035
2.18971
2.17387
2.17183
2.14818
2.14259
2.13067
2.12702
2.12286
2.12002
2.10273
2.10147
2.09207
2.07886
2.07127
2.05866
2.05775
2.04821
2.04306
2.04245
1.99257
1.98978
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Affymetrix
ID
8116418
7906995
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8156571
7936322
7979710
7922773
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7972239
7922976
8063634
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8026047
7974316
8154962
7922889
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AB016789
BT006860
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BC146783
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AF228603
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AF480560
AF198532
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AK299392
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AF498971
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AF088982
ENST00000367498
BC070079
ENST00000424392
AF146696
ENST00000376447
AJ420528
AK290572
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AB078145
ENST00000378827
U66075
BC130323
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Gene Name
GFPT2
UCK2
AMACR
FNDC1
MIR27B
GPAM
PLEK2
NCF2
ABCA1
E2F7
BNC1
SLITRK6
PTGS2
MGC4294
SOCS6
CHRNA9
MIR24-1
LEF1
DIXDC1
TSHZ3
ETV6
PPP1R3C
IGFBP3
ATP10A
RHOB
PHLDB1
JUNB
FRMD6
DNAJB5
IVNS1ABP
LRRC32
PHF16
FOXP1
RASEF
DCBLD1
IL11
SPECC1
GALNT10
BMP2
GATA6
SYT14
MFAP3L

Fold
Increase
1.98967
1.98699
1.97704
1.9678
1.96393
1.95685
1.95078
1.94535
1.94403
1.93429
1.93384
1.93138
1.92186
1.91941
1.91887
1.91164
1.91017
1.90975
1.90939
1.9092
1.90186
1.89232
1.88748
1.88652
1.88318
1.87993
1.87672
1.8761
1.87319
1.87315
1.86387
1.86357
1.86169
1.85336
1.85226
1.84543
1.84376
1.82627
1.81767
1.81052
1.80486
1.79877
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Affymetrix
ID
8095767
8026198
7965112
7922326
8092836
8054997
8056257
7999909
7944722
8157253
8072705
8157802
8142415
8058477
8047738
8010061
8025402
8151816
7956271
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8155192
7943998
7901993
8141241

Genbank
Accession
AK074237
ENST00000440752
ENST00000550006
ENST00000385214
BC031569
AK074577
U76833
AF181862
AF425252
ENST00000374232
AF279143
ENST00000385004
AK299901
AK297312
AL833606
AF200328
AB056477
BC022010
AF016509
AK056628
AK091288
BC000234
AK299361
ENST00000361125

Gene Name
C4orf26
ZSWIM4
PAWR
MIR3120
CPN2
MAP3K2
FAP
GPRC5B
UBASH3B
SNX30
RASD2
MIR181B2
C7orf60
KLF7
NRP2
SPHK1
ANGPTL4
GEM
HSD17B6
SORBS2
GLIPR2
NNMT
CACHD1
SMURF1

Fold
Increase
1.79371
1.79067
1.78964
1.78538
1.77686
1.77627
1.77509
1.76782
1.75863
1.75667
1.75216
1.74598
1.74074
1.73553
1.73487
1.72518
1.72498
1.72429
1.7231
1.72124
1.71552
1.711
1.70334
1.70312
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